MOLECULAR PLANT PATHOLOGY (2015) 16(2), 150-163

Derivative of plant phenolic compound inhibits the type III secretion system of *Dickeya dadantii* via HrpX/HrpY two-component signal transduction and Rsm systems

YAN LI¹, WILLIAM HUTCHINS², XIAOGANG WU², CUIRONG LIANG³, CHENGFANG ZHANG³, XIAOCHEN YUAN², DEVANSHI KHOKHANI², XIN CHEN³, YIZHOU CHE², QI WANG^{1,*} AND CHING-HONG YANG^{2,*}

¹The MOA Key Laboratory of Plant Pathology, Department of Plant Pathology, College of Agronomy & Biotechnology, China Agricultural University, Beijing 100193, China China

²Department of Biological Sciences, University of Wisconsin, Milwaukee, WI 53211, USA ³School of Pharmaceutical & Life Sciences, Changzhou University, Jiangsu 213164, China

SUMMARY

The type III secretion system (T3SS) is a major virulence factor in many Gram-negative bacterial pathogens and represents a particularly appealing target for antimicrobial agents. Previous studies have shown that the plant phenolic compound *p*-coumaric acid (PCA) plays a role in the inhibition of T3SS expression of the phytopathogen Dickeya dadantii 3937. This study screened a series of derivatives of plant phenolic compounds and identified that trans-4-hydroxycinnamohydroxamic acid (TS103) has an eight-fold higher inhibitory potency than PCA on the T3SS of D. dadantii. The effect of TS103 on regulatory components of the T3SS was further elucidated. Our results suggest that TS103 inhibits HrpY phosphorylation and leads to reduced levels of hrpS and *hrpL* transcripts. In addition, through a reduction in the RNA levels of the regulatory small RNA RsmB, TS103 also inhibits hrpL at the post-transcriptional level via the *rsmB*-RsmA regulatory pathway. Finally, TS103 inhibits hrpL transcription and mRNA stability, which leads to reduced expression of HrpL regulon genes, such as hrpA and hrpN. To our knowledge, this is the first inhibitor to affect the T3SS through both the transcriptional and post-transcriptional pathways in the soft-rot phytopathogen *D. dadantii* 3937.

Keywords: plant phenolic compound, Rsm system, T3SS inhibitor, type III secretion system, two-component signal transduction system.

INTRODUCTION

Antibiotic treatment is the most commonly used strategy to control pathogenic infections. However, most antibiotics kill bacteria by inhibiting cellular processes essential for survival, which

*Correspondence: Email: chyang@uwm.edu or wangqi@cau.edu.cn

leads to strong selective pressure to develop resistance against antibiotics (Cegelski et al., 2008; Escaich, 2008; Rasko and Sperandio, 2010). In the face of increasing antibiotic resistance, the targeting of bacterial virulence factors rather than bacterial survivability provides a novel alternative approach for the development of new antimicrobials, as virulence-specific therapeutics would offer a reduced selection pressure for antibiotic-resistant mutations (Escaich, 2008; Rasko and Sperandio, 2010). The type III secretion system (T3SS) represents a particularly appealing target for antimicrobial agents because it is a major virulence factor in many Gram-negative plant and animal pathogens (Cornelis, 2006; Tang *et al.*, 2006; Waterman and Holden, 2003; Yang *et al.*, 2002). The T3SS in phytobacteria, also known as the hypersensitive response and pathogenicity (Hrp) system, is a syringe needle-like structure which is responsible for the secretion and translocation of effector proteins into the host cells, where the effector proteins subvert or inhibit the host cell's defences or facilitate pathogenicity (Alfano and Collmer, 1997; Galán and Collmer, 1999; Ghosh, 2004; Grant et al., 2006; Hueck, 1998; Yang et al., 2005).

Dickeya dadantii 3937 (formerly named Erwinia chrysanthemi), a member of the Enterobacteriaceae family, is a Gram-negative pathogen which causes soft rot, wilt and blight diseases on a wide range of plant species (Bauer et al., 1994). D. dadantii possesses a T3SS, which is encoded by the hrp gene cluster and thought to be coordinately regulated by various host and environmental factors (Nasser et al., 2005; Yang et al., 2002). Similar to many phytopathogens, the expression of the T3SS of D. dadantii 3937 is repressed in nutrient-rich media, but induced in the plant apoplast or in nutrient-deficient inducing medium, which is considered to mimic plant apoplastic conditions (Galán and Collmer, 1999; Tang et al., 2006). The well-studied T3SS of D. dadantii is regulated by the master regulator HrpL, which is a member of the extracytoplasmic function (ECF) family of alternative sigma factors that up-regulate many hrp genes downstream of the T3SS regulatory cascade, such as hrpA (encoding a structural protein of the T3SS pilus), dspE (encoding a T3SS effector) and hrpN (encoding a



Fig. 1 Regulatory network controlling the *Dickeya dadantii* type III secretion system (T3SS). The *D. dadantii* T3SS is regulated by the HrpX/HrpY-HrpS-HrpL and GacS/GacA-*rsmB*-RsmA-HrpL regulatory pathways. The two-component signal transduction system HrpX/HrpY activates *hrpS*, which encodes a σ^{54} enhancer. HrpS is required for the expression of the alternative sigma factor, *hrpL*. HrpL activates the expression of genes encoding the T3SS apparatus and its secreted substrates. RsmA is a small RNA-binding protein that acts by decreasing the half-life of *hrpL* mRNA. GacS/GacA up-regulates the expression of *rsmB*, which increases the mRNA level of *hrpL* by sequestering RsmA. From this study, we observed that TS103 altered the *hrpA* promoter activity through both the HrpX/HrpY-HrpS-HrpL and *rsmB*-RsmA-HrpL pathways. TS103 inhibits *hrpL* at the post-transcriptional level through a decrease in expression of *rsmB*. In addition, TS103 inhibits *hrpS* transcription through suppression of phosphorylation of HrpY and also post-transcriptionally inhibits *rpoN*. \bot , negative control; \rightarrow , positive control. IM: Inner Membrane; OM: Outer Membrane.

harpin protein) (Fig. 1) (Chatterjee et al., 2002; Wei et al., 1992; Yang et al., 2010; Yap et al., 2005). The expression of hrpL is regulated at both the transcriptional and post-transcriptional levels. HrpX/HrpY-HrpS regulates *hrpL* at the transcriptional level. A two-component signal transduction system (TCSTS) HrpX/HrpY, encoded by genes in the centre of the *hrp* gene cluster, positively regulates *hrpS*, which encodes a σ^{54} enhancer-binding protein (Fig. 1) (Tang *et al.*, 2006). HrpS interacts with the σ^{54} (RpoN)containing RNA polymerase holoenzyme and initiates the transcription of *hrpL* (Fig. 1) (Chatterjee *et al.*, 2002; Yap *et al.*, 2005). The regulator of secondary metabolites (Rsm) RsmA-RsmB pair regulates hrpL at the post-transcriptional level. RsmA, a small RNA-binding protein, promotes *hrpL* mRNA degradation (Fig. 1) (Chatterjee et al., 2002; Cui et al., 1995). RsmB, an untranslated regulatory small RNA, binds to the RsmA protein and neutralizes the activity of RsmA on hrpL mRNA degradation by forming an inactive ribonucleoprotein complex with RsmA (Chatterjee et al., 2002; Liu et al., 1998) (Fig. 1). The global regulatory TCSTS, GacS/ GacA, up-regulates the transcription of the regulatory small RNA RsmB (Tang et al., 2006). In addition to GacS/GacA, other regulators have been identified that control the expression of rsmB in the soft-rot pathogens Pectobacterium and Dickeya. KdgR, an IcII-like protein, has been reported to negatively control the transcription of *rsmB* by binding within the transcribed region of the *rsmB* gene in *P. carotovorum* (Miller *et al.*, 2000). Polynucleotide phosphorylase (PNPase) has been reported to decrease the amount of functional *rsmB* transcripts in *D. dadantii* (Zeng *et al.*, 2010).

In response to microbial attack, plants activate defence responses which lead to the induction of a broad spectrum of antimicrobial defences (Montesano et al., 2005; Van Loon, 2000). These induced defences are regulated by a network of interconnecting signal transduction pathways and eventually lead to the production of defence molecules, such as phenylpropanoids (Dixon and Paiva, 1995; Feys and Parker, 2000; Hahlbrock and Scheel, 1989). Phenylpropanoids are a group of secondary metabolites produced by plants from L-phenylalanine. Our previous reports have shown that the plant phenolic compound p-coumaric acid (PCA), an intermediate in phenylpropanoid biosynthesis, plays a role in the inhibition of T3SS expression of D. dadantii 3937 (Li et al., 2009). With the aid of structure-activity relationship (SAR) studies, the para positioning of the hydroxyl group in the phenyl ring and the double bond in PCA have been predicted previously to be essential for its inhibitory activity (Li et al., 2009). As the regulatory mechanism of the T3SS of D. dadantii 3937 is well understood, to develop T3SS inhibitors which are more potent than PCA, a series of derivatives of plant phenolic compounds were screened using D. dadantii 3937 as a model organism. One derivative, TS103, which showed an eightfold higher potency in the inhibition of the T3SS vs. PCA, was selected and the regulators responsible for the inhibition of T3SS gene expression by TS103 were further elucidated. Our results showed that TS103 inhibits the T3SS through both the HrpX/HrpY TCSTS and Rsm systems.

RESULTS

R

но

R

R#

TS101

Screening for highly potent T3SS inhibitors of D. dadantii

In our previous work, the phenolic acid PCA was found to inhibit T3SS gene expression of *D. dadantii* 3937 at a concentration of 100 µM (Li et al., 2009). To identify T3SS inhibitors which have higher potency in the inhibition of T3SS expression, 50 derivatives of plant phenolic compounds (Fig. 2) at a concentration of 100 μ M were first screened by monitoring the promoter activity of *hrpA*.



The hrpA gene encodes the T3SS pilus, which is required for the translocation of effector proteins into plant cells and is located downstream in the T3SS regulatory pathway (Fig. 1). A reporter plasmid, pPhrpA, which carries a hrpA-gfp transcriptional fusion, was used to measure the effects of the derivatives of plant phenolic compounds on *hrpA* expression (Table 1). The wild-type cells containing pPhrpA were grown in T3SS-inducing medium (MM) supplemented with each of the compounds at a concentration of 100 µM. Green fluorescent protein (GFP) intensity, which is a measurement of hrpA promoter activity, was assayed by flow cytometry. Among the derivatives of the plant phenolic compounds screened, 13 compounds at a concentration of 100 μ M showed strong inhibition of T3SS gene expression of *D. dadantii*, in which the level of hrpA promoter activity was reduced by more than 50% of the level in MM at both 12 and 24 h of growth after repeated measurements (Table 2).

To identify inhibitors that exhibit higher efficacy of T3SS inhibition, the hrpA expression of D. dadantii cells grown in MM supplemented with inhibitors at a concentration of 10 µM instead of 100 μ M was further examined. PCA was used as a reference, in which hrpA expression was inhibited at a concentration of 100 µM, but not at 10 μM (Table 2 and Fig. S1, see Supporting Information)



TS125: R=4-OMe TS128: R=4-Br TS129: R=2-OH TS130 R=3-OH TS131: R=3,4-diOH TS132: R=H TS146: R=4-CHO TS164: R=4-benzylcarbonyl

TS116: R'=H TS118: R'=4-Me

Strains and plasmids	Relevant characteristics	Reference or source		
Strains				
Escherichia coli				
E. coli S17-1 λ-pir	λ- <i>pir</i> lysogen of S17-1; Sp ^R	Sanchez-Romero <i>et al</i> . (1998)		
Dickeya dadantii				
3937	Wild-type, <i>Saintpaulia</i> (African violet) isolate	Hugouvieux-Cotte-Pattat, N. (Microbiologie Adaptation et Pathogenie CNRS, INSA de Lyon, Universite de Lyon, Lyon F-69622, France)		
$\Delta hrpY$	hrpY deletion mutant; Km ^R	This study		
∆hrpYD57A	3937 derivative in which the conserved aspartate residue at position 57 in HrpY was changed by nonconservative substitution to alanine; Km ^R	This study		
$\Delta gacA$	gacA deletion mutant; Km ^R	This study		
$\Delta gacA::gacA$	$\Delta gacA$ with chromosomal insertion of <i>lacY-gacA-cm-prt</i> ; Km ^R , Cm ^R	This study		
Δpnp	pnp deletion mutant; Km ^R	Zeng <i>et al</i> . (2010)		
∆kdgR	<i>kdgR</i> deletion mutant; Km ^R	This study		
3937::OpgG-His₀	3937 with a 6 $ imes$ His epitope sequence tagged to the C-terminus of OpgG	Laboratory stock		
Plasmids				
pAT	pProbe-AT, promoter-probe vector; Ap ^R	Miller <i>et al</i> . (2000)		
pPhrpA	pAT derivative with PCR fragment containing <i>hrpA</i> promoter region; Ap ^R	Yang <i>et al</i> . (2008a)		
pPhrpN	pAT derivative with PCR fragment containing <i>hrpN</i> promoter region; Ap ^R	Yang <i>et al</i> . (2007)		
pPhrpL	pAT derivative with PCR fragment containing <i>hrpL</i> promoter region; Ap ^R	Yang <i>et al</i> . (2007)		
pPhrpS	pAT derivative with PCR fragment containing <i>hrpS</i> promoter region; Ap ^R	Li <i>et al</i> . (2009)		
pPrpoN	pAT derivative with PCR fragment containing <i>rpoN</i> promoter region; Ap ^R	Yi <i>et al</i> . (2010)		
pPrsmB	pAT derivative with PCR fragment containing <i>rsmB</i> promoter region; Ap ^R	This study		
pWM91	Sucrose-based counter-selectable plasmid; Ap ^R	Metcalf <i>et al</i> . (1996)		
pKD4	Template plasmid for kanamycin cassette; Km ^R	Datsenko and Wanner (2000)		
pGEM-T Easy	Cloning vector; Ap ^R	Promega (Madison, WI, USA)		
phrpY	pGEM-T Easy derivative with PCR fragment containing the <i>hrpY</i> ORF and its flanking regions; Ap ^R	This study		
phrpYD57A	phrpY derivative in which the conserved aspartate residue at position 57 in HrpY was changed by nonconservative substitution to alanine; Ap ^R	This study		
pTCLSCm	6.4-kb lacY-cm-prt region cloned in pGEM-T Easy; Cm ^R	Yap <i>et al</i> . (2008)		
pML123	Broad-host-range cloning vector; Gm ^R	Labes <i>et al</i> . (1990)		
pMLkdgR	Derivative of pML123 carrying <i>kdgR</i> ; Gm ^R	This study		
pCL1920	Expression vector; Sp ^R	Lerner and Inouye (1990)		
pCLhrpXY	Derivative of pCL1920 carrying <i>hrpXY</i> operon; Sp ^R	This study		

Table 1 Strains and plasmids used in this study.

Ap^R, ampicillin resistance; Cm^R, chloramphenicol resistance; Km^R, kanamycin resistance; Gm^R, gentamicin resistance; ORF, open reading frame; Sp^R, spectinomycin resistance.

(Li et al., 2009). Our results showed that the level of hrpA expression of D. dadantii 3937 cells grown in MM supplemented with three of the inhibitors (TS103, TS126 and TS131) at a concentration of 10 μ M was less than 50% of the level in MM at 12 h of growth (Fig. S1). Among these three compounds, the addition of TS103 at a concentration of 10 µM resulted in the greatest reduction in hrpA expression at 12 h of bacterial growth, in which the level of hrpA expression of *D. dadantii* cells grown in MM supplemented with TS103 was less than 25% of the level in MM (Fig. S1). The addition of all the selected inhibitors at a concentration of 1 μ M did not result in a significant reduction in hrpA promoter activity at 12 h of bacterial growth (data not shown). In addition, growth inhibition was not observed in TS103 at the tested concentrations (Figs S2 and S3, see Supporting Information). These results suggest that TS103 has the highest potency of T3SS inhibition among all the derivatives of plant phenolic compounds screened in this study. To further compare the inhibitory efficacy on the T3SS between TS103 and PCA, we tested the half-maximal inhibitory concentration (IC₅₀) of these two compounds on T3SS expression. Here, IC₅₀ is defined as the concentration of compound that is required for the inhibition of 50% of the *hrpA* promoter activity compared with MM. The results showed that the IC₅₀ of TS103 was 2.2 μ M, which is one-eighth of that of PCA (Fig. 3).

TS103 inhibits the transcription and production of T3SS structural- and harpin-encoding genes

To confirm the inhibitory effect of TS103 on the T3SS of *D. dadantii*, the promoter activities and mRNA levels of two representative *hrp* genes, *hrpA* and *hrpN*, were examined in the presence and absence of TS103. Similar to the results obtained from the screening above (Table 2), a lower *hrpA* promoter activity was observed in MM supplemented with TS103 compared with that in MM alone (Table 3). Considerably lower promoter activity of *hrpN* was observed in the cells grown in MM supplemented with TS103 in comparison with that in MM (Table 3). Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis revealed a significant decrease in *hrpA* (relative expression ratio

Table 2 The hrpA expression of Dickeya dadantii 3937 in type III secretion system-inducing medium (MM) and MM supplemented with different derivatives of plant phenolic compounds.

Phenolic compound* Ave MH ± 5D # %MM Ave MH ± 5D # %MM MM 34.4 ± 0.8 90.6 ± 11.7 131.5 131.7 131.5 131.7 131.6 131.2 131.5 131.7 131.6 131.2 131.5 131.7 131.6 131.2 131.5 131.7 131.6 131.2 131.6 131.4 131.2		12 h		24 h	
MM 35.4 ± 0.8 90.6 ± 11.7 15100, ethyl farae 2.4 (methosphernyl) 1-cyclopopanecarboxylate 45.5 ± 0.47 128.2 119.1 ± 22.1 119.1 ± 22.1 15101, ethyl farae 2.6 (methosphernyl) 1-cyclopopanecarboxylate 45.5 ± 0.47 28.7 69.8 ± 10.5 62.0 15101, ethyl farae 2.6 (methosphernyl) 1-cyclopopanecarboxyla eth 30.1 ± 0.17 86.1 ± 0.21 119.1 ± 0.8* 122.1 ± 12.7 129.8 ± 0.44 ± 1.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.1 ± 0.8* 120.2 ± 0.8* 0.64.1 ± 0.7* 120.1 ± 0.8* 120.1 ± 0.8* 120.2 ± 0.8* 0.64.1 ± 0.7* 120.1 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.1 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8* 120.2 ± 0.8*<	Phenolic compound†	Ave MFI ± SD‡	%MM§	Ave MFI ± SD	%MM
15100. ethyl ram-2.44-metholypheryl-1-syckopopanecarborylate 45.3 ± 3.4 128.2 119.1 ± 2.21 131.5 15100. rethyl parse-annale 27.5 ± 0.27 406 19.9 ± 0.5' 22.0 15102. roms-4-hydroxyninanolydycominanolyd comin aid 3.0 ± 0.1' 8.6 12.9 ± 1.8' 13.2 15102. roms-4-hydroxyninanolydycominanolyd comin aid 3.0 ± 0.1' 8.6 12.9 ± 1.8' 13.2 15105. roms-2-4-tenebroxynberyl-1-cyclopopanecarborylic aid 22.9 ± 2.2' 23.8 12.9 ± 1.8' 13.4 15105. roms-2-4-tenebroxynberyl-1-cyclopopanecarborylic aid 13.6 ± 2.3' 80.9 18.0 ± 1.9' 13.4 15105. roms-2-4-tenebroxynberyl-1-cyclopopanecarborylic aid 13.6 ± 2.3' 80.9 18.0 ± 1.9' 13.4 15105. roms-2-4-tenebroxynberyl-1-cyclopopanecarborylic aid 23.9 ± 5.2 67.7 67.4 60.7 ± 6.4 67.9 15111. roms-4-tenebroxynberyl-1-cyclopopanecarborylic aid 23.9 ± 5.2 67.7 74.1 ± 1.2' 63.3 15111. roms-4-tenebroxynberyl-1-cyclopopanecarborylic aid 23.9 ± 5.2 67.7 64.7 ± 2.2 63.8 15111. roms-6-tenterynberox-1-cyclopopanecarborylic aid 23.9 ±	MM	35.4 ± 0.8		90.6 ± 11.7	
15101, merely jarze-coursarie 17,5 ± 0.7" 99 19,9 ± 0.5" 22.0 15102, most-4ybitoxycinnamic 21,1 ± 1.2" 597 60.8 ± 10.6 67.1 15103, most-4ybitoxycinnamicyl achd 30.2 ± 1.4" 42.4 58.4 90.9 15103, most-24-methoxybitemyl-1-cyclopropanecarboxylic 22.9 ± 2.6" 64.8 82.4 ± 5.8 90.9 15105, most-24-methoxybitemyl-1-cyclopropanecarboxylic 30.6 ± 2.5 89.3 109.9 ± 19.8 80.4 ± 4.1" 15105, most-24-hipdicoxybitemyl-inspectatoxylic 33.7 ± 6.3 100.8 81.5 ± 3.8 89.9 15106, most-24-hipdicoxybitemyl-inspectatoxylic 33.7 ± 6.3 100.8 81.5 ± 3.8 89.9 15107, most-4-hipdicoxybitemyl-inspectatoxylic 33.7 ± 6.3 100.8 81.5 ± 3.8 89.9 15117, most-4-hipdicoxybitemyl-inspectatoxylic 23.8 ± 4.3 67.4 66.7 77.6 ± 9.4 15117, most-4-hipdicoxybitemyl-inspectatoxylic 23.8 ± 4.3 67.4 66.7 ± 5.4 66.9 15117, most-4-hipdicoxybitemyl-inspector 73.4 ± 0.9 73.1 ± 0.2 99.2 73.1 ± 0.2 99.2 73.1 ± 0.2 99.2 73.1 ± 2.0 99.9 73.1 ± 2.0 99.2	TS100, ethyl <i>trans</i> -2-(4-methoxyphenyl)-1-cyclopropanecarboxylate	$45.3 \pm 3.4^{*}$	128.2	119.1 + 22.1	131.5
15102, more-4-hydroxydnamnidydrawina add 21.1 ± 1.2* 99.7 60.8 ± 10.6 67.1 15104, more-4-hydroxydnamnidydrawina add 3.0 ± 0.1* 8.6 12.9 ± 1.8* 13.2 15104, more-4-hydroxydnamnidydrawina add 2.9 ± 2.6* 64.8 82.2 ± 1.8* 13.2 15105, more-2-de-hydroxydnenyl-1-cycloropranecatboxylic add 3.1 6.2 ± 5 89.3 49.4 ± 4.1* 54.5 15105, more 4-hendroxydnenyl-1-cycloropranecatboxylic add 3.1 6.2 ± 5 89.3 10.9 ± 19.8 120.3 15107, more 4-hendroxydnenyl-1-cycloropranecatboxylic add 2.3 ± 2.5 8.9.3 10.9 ± 19.8 120.3 15107, more 4-hendroxydnenyl-1-cycloropranecatboxylic add 2.3 ± 1.4 1.6 ± 2.5 8.9.3 10.9 ± 19.8 120.3 15107, more 4-hendrylaminocinnamic add 2.9 ± 5.2 6.7 6.47 ± 7.2 6.63 7.7 5.47 ± 7.2 6.63 ± 5.7 7.5 € 4.64 6.7 6.4 6.7 10.7 5.4 ± 6.7 7.7 ± 6.4 6.7 10.2 10.6 ± 5.5 10.2 11.1 12.2 10.6 ± 5.5 10.2 10.4 ± 6.7 10.7 ± 6.4 6.7 11.4 10.4 ± 5.5 10.2 11.4 ± 6.7 17.1 ± 9.1 12.2	TS101 methyl <i>para-</i> coumarate	$175 \pm 0.7^*$	49.6	199+05*	22.0
15103. ross-4-lydroxychmannohydroxamic acid 6.7 ± 0.3* 2.4 × 1.4 1.9 ± 0.8* 11.2 15104. pare-companyl eknolu 3.0 ± 0.1* 8.6 12.9 ± 1.8* 12.2 15105. ross-4-lydroxychenyl-hydropopanecarboxylic acid 2.9 ± 2.6* 6.4.8 8.2.4 ± 5.8 90.9 15105. ross-4-lydroxychenyl-hydropopanecarboxylic acid 3.6 ± 2.5 ± 0.8* 9.94 ± 4.1* 9.8 49.4 ± 1.1* 9.8.4 15105. ross-4-lydroxychenyl-hydropopanecarboxylic acid 3.6 ± 2.5 ± 0.8* 10.9.4 ± 0.2* <	TS102 <i>trans</i> -4-hydroxycinnamide	21 1 + 1 2*	59.7	60.8 ± 10.6	67.1
17104, grave-quineryl-alcohol 30 ± 0.1* 8.6 12.9 ± 1.8* 14.2 17504, grave-dunedhopphenyl-t-ryckopropanecarboxylate 10.5 ± 0.8* 29.8 49.4 ± 4.1* 55.5 17506, grave-dunedhopphenyl-t-ryckopropanecarboxylate 10.5 ± 0.8* 29.8 49.4 ± 4.1* 55.5 17507, trave-3-4-heydoxynbenyl-t-ryckopropanecarboxylate 10.5 ± 0.8* 29.8 10.4 ± 1.1* 54.8 12.9 ± 1.2* 12.9 12.1 ± 17.9 13.4 10.8 15.1 ± 3.2* 12.9 12.2 ± 1.1* 13.4 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 13.1* 14.1* 13.1*	TS103 trans-4-bydroxycinnamobydroxamic acid	87+03*	24.7	11 9 + 0.8*	13.2
17105 cmar-24-methosphengh-t-cyclopropanecarboxylic acid 22.9 ± 2.6 r 6.8 12.4 ± 5.8 90.9 17105 cmbr 24-bytdoxyphengh-t-cyclopropanecarboxylic acid 45.9 ± 7.7 12.9 12.1 ± 17.9 13.7 17105 cmbr 24-bytdoxyphengh-t-cyclopropanecarboxylic acid 45.9 ± 7.7 57.9 12.7 17.9 13.7 17107 cmar-4-chlorocinnamic acid 35.7 ± 6.3 10.8 81.5 ± 3.8 89.9 17117 cmar-4-chlorocinnamic acid 23.9 ± 5.2 6.7.7 5.4 ± 7.7 6.8 5.4 ± 7.7 6.8 12.7 6.8 12.7 6.3 10.8 81.5 ± 3.8 89.9 15.1 13.7 6.4 ± 6.0 6.7 7.7 5.4 ± 7.7 6.3 10.3 7.5 7.7 5.4 ± 7.7 7.5 7.7 5.7 7.5 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7 5.7 7.7	TS103, nans 4 hydroxychildholydroxdille ded	$3.0 \pm 0.1*$	86	17.9 ± 0.0	14.2
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS105, trans-2-(A-methovynhanyl)-1-cyclopropapacarboyylic acid	22.0 ± 0.1	64.8	82 4 + 5 8	QA Q
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TS106, atbul trans 2 (4 hudrovurbenul) 1 cyclopropanecarboxyle deld	22.0 ± 2.0 10 5 ± 0.8*	20.8	40.4 ± 0.0	54.5
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TS100, etilyi <i>italis</i> -z-(4-fiyuloxyphenyi)-1-cyclopropanecarbowile acid	10.5 ± 0.8	120.0	49.4 ± 4.1 122.1 ± 17.0	124.5
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TS107, trans-2-(4-hydroxypheny)-1-cyclopropanecarboxync acu	45.5 ± 2.7	123.5	122.1 ± 17.5	134.7
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TS100, <i>trans</i> 4-phenyichilianiic aciu	31.0 ± 2.3	09.5	109.0 ± 19.0	120.5
1510, 17, 1742-4-1007004malmic acid 03.4 ± 0.0" 179.4 183.8 ± 19.2 202.6 1511, 1743-4-100004malmic acid 23.9 ± 5.2 67.7 67.4 67.7 57.6 77.1 19.1 77.7 19.7 17.7 19.7 17.7 19.7 19.7 77.6 77.6 77.6 77.6 77.6 77.6 77.6 77.6 77.6 77.6 77.7 77.6 77.7 77.6 77.7 77.7 77.7 77.7 77.7 77.7 77.7	TS 109, trans-4-chlorocinnamide	35.7 ± 6.3	100.8	81.5±3.8	89.9
1311, 7ara-4-dromodinamic add 23 ± 5.2 67.7 54.7 ± 7.2 60.3 1311, 7ara-4-triflucomethylainnomic aid 24 ± 4.3 67.4 60.7 ± 6.4 67.0 1311, 7ara-4-triflucomethylainnomic aid 24 ± 4.03* 69.1 68.5 ± 5.7 75.6 M 51.4 ± 6.7 77.1 ± 9.1 711 7114, diethyl trans-2(4-hydroxypheryl)-vinylphosphonate 53.4 ± 1.6 10.7 76.5 ± 5.6 99.2 13115, 7ara-2-coumarylphthalimide 24.3 ± 1.5* 112.7 79.6 ± 3.3 103.2 71.6 71.7 73.8 112.0 94.9 91.8 71.4 70.8 88.1 71.7 79.6 ± 3.3 103.2 71.5 71.4 70.6 88.2 10.4 88.5 112.0 91.9 71.4 70.8 88.1 71.7 70.6 88.6 89.2 10.6 77.7 ± 6.8 100.8 75.12 77.6 8.0 94.0 83.8 25.6 2.0 94.2 10.6 77.7 ± 6.8 100.8 151.2 77.7 ± 6.8 100.8 151.2 77.4 10.3 17	ISTIU, trans-4-nuorocinnamic acid	$63.4 \pm 8.0^{\circ}$	179.4	183.8 ± 19.2"	202.8
15 11, 7, 7, 3-4-1000 2.3 ± 7.4.3 67.4 60.7 ± 6.4 67.0 15 11, 7, 7, 7, 14 - 01 51.4 ± 6.7 77.1 ± 9.1 15 11, 7, 7, 7, 14 - 01 76.5 ± 5.6 99.2 15 11, 7, 7, 7, 14 - 01 76.5 ± 5.6 99.2 15 11, 7, 7, 7, 14 - 01 76.5 ± 5.6 99.2 15 11, 7, 7, 7, 14 - 01 77.1 ± 9.1 77.1 ± 9.1 15 11, 7, 7, 7, 14 - 01 77.1 ± 9.1 77.1 ± 9.1 15 11, 7, 7, 7, 7, 12 - 01 77.1 ± 9.1 77.1 ± 9.1 15 11, 7, 7, 7, 14 - 01 77.1 ± 9.1 77.1 ± 9.1 15 11, 7, 7, 7, 4 + 0.0 77.1 ± 9.1 77.1 ± 9.1 15 11, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7,	ISIII, trans-4-bromocinnamic acid	23.9 ± 5.2	67.7	54.7 ± 7.2	60.3
15112, grans-4-tritluciometry(cimamic add 24.4 ± 0.9" 69.1 68.5 ± 5.7 7.5 b TS114, diethy trans-2-(4-hydroxypheny)-vinylphosphonate 51.4 ± 6.7 77.1 ± 9.1 71.5 ± 5.6 99.2 TS115, grans-2-triphydroxypheny)-vinylphosphonate 23.4 ± 1.5" 112.7 79.6 ± 3.3 103.2 TS116, Ark-2-triphydroxypheny)-vinylphosphonate 24.3 ± 1.5" 47.2 39.3 ± 3.5" 51.0 TS117, Arac-coumarylphythalimide 59.9 ± 1.6 112.7 79.6 ± 6.0 89.1 TS117, Arac-coumarylphythalimide 59.0 ± 0.4 114.7 83.8 ± 1.7 108.8 TS112, Arac-chethoxychinarmylphythalimide 59.9 ± 1.6 112.7 66.6 ± 6.0 89.1 TS12, Arac-chethoxychinarmylphythalimide 59.9 ± 2.6 97.0 68.6 ± 6.0 89.1 TS12, Arac-chethoxychinarmylphythalimide 36.4 ± 1.8 75.1 60.9 ± 0.8 70.0 TS12, Arac-chethoxychinarmylphythalimide 24.4 ± 0.3" 51.4 60.9 ± 0.4 74.9 TS12, Arac-chethoxychinarmylphythalimide 74.4 ± 0.3" 75.2 13.4 ± 0.3" 71.4 ± 0.3" TS12, Arac-chethoxychinarmylphythalimide 73.4 ± 0.2" 15.2 13.4 ± 0.3" 71.4	ISII2, trans-4-dimethylaminocinnamic acid	23.8 ± 4.3	67.4	60.7±6.4	67.0
MM 514 d. 66.7 77.1 ± 9.1 ST14, diethyl trans-2(4-hydroxyphenyl)-vinylphosphona tei 55.4 ± 1.0 107.8 76.5 ± 5.6 99.2 ST15, fam-2-(4-hydroxyphenyl)-vinylphosphonic acid 57.9 ± 1.6 112.7 79.6 ± 3.3 1032. ST15, fam-2-(4-hydroxyphenyl)-vinylphosphonic acid 59.0 ± 0.4 114.7 83.8 ± 1.7 0.84 ST18, M/d-metoxycinnamylphthalimide 49.8 ± 1.6 95.0 66.2 ± 10.4 86.5 ST12, trans-4-methoxycinnamylphthalimide 49.9 ± 2.6 97.0 66.8 ± 6.0 89.1 ST20, ethyl trans-2/4-hydroxyphenyl)-ethenylsulphonate 38.6 ± 1.8 75.1 ± 0.0 111.1 72.2 ± 10.6 93.7 ST22, trans-4-hydroxymethyl/chamyl-atemylsulphonate 38.6 ± 1.8 75.1 ± 0.0 77.7 ± 6.8 100.8 ST24, trans-4-hydroxymethyl/chaminic acid 17.4 ± 0.3* 37.4 101.6 77.7 ± 6.8 100.8 ST24, trans-4-hydroxymethyl/chaminic acid 17.4 ± 0.3* 37.4 101.3* 17.4 ± 0.3* 17.4 ± 0.3* ST24, trans-4-hydroxymethyl/chaminic acid 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3* 17.4 ± 0.3*	IS113, trans-4-trifluoromethylcinnamic acid	$24.4 \pm 0.9^{\circ}$	69.1	68.5 ± 5.7	/5.6
15114, diethyl trans-2-(4-hydroxyphenyl)-intyphosphonate 55.4 ± 1.0 107.8 76.5 ± 5.6 99.2 15115, trans-2-(4-hydroxyphenyl-vinyphosphonic aid 27.9 ± 1.6 17.7 76.5 ± 5.6 19.2 15117, trans-2-(4-hydroxyphenyl-vinyphosphonic aid 27.9 ± 1.6 17.7 76.5 ± 3.5* 15.0 15117, trans-2-unanylphinhalimide 59.0 ± 0.4 11.4 83.8 ± 1.7 108.8 15119, trans-4-methoxycinnamylphinhalimide 47.8 ± 3.2 93.0 68.8 ± 10.4 88.5 15121, trans-2-(4-methoxycinnamylphinhalimide) 57.1 ± 1.00 11.1 77.2 ± 0.6 93.7 15121, trans-2-(4-methoxycinnamylphinhamylphinhamic aid 157.1 ± 1.00 11.1 77.2 ± 0.6 97.0 15121, trans-2-(4-methoxycinnamylphinhamylphinhamic aid 17.4 ± 0.9* 33.8 25.6 ± 2.0* 10.6 97.7 15124, trans-4-methoxycinnamylphinhamic aid 17.4 ± 0.9* 33.8 25.6 ± 2.0* 17.4 ± 0.9* 15126, trans-4-methoxycinnamylphinhamic aid 17.4 ± 0.9* 33.8 25.6 ± 2.0* 17.4 ± 0.9* 15126, trans-4-methoxycinnamylphinhalimide 7.8 ± 0.2* 15.2 13.4 ± 0.3* 17.4 ± 0.9* 15126, trans-4-dethoxycinnamylphinhalimide	MM	51.4 ± 6.7		77.1 ± 9.1	
S115, Taras-2-(4-hydroxyphenyl-oinylphasphonic acid 57.9 ± 1.6 112.7 79.6 ± 3.3 103.2 S115, M., Vazar-coumarylphthalimide 24.3 ± 1.5* 47.2 39.3 ± 3.5* 51.0 S115, M., Vazar-coumarylphthalimide 59.0 ± 0.4 11.4 83.8 ± 1.7 108.8 S119, M., Harne-Honoxycinnamylphthalimide 59.0 ± 0.4 11.4 78.8 ± 1.1 108.8 S112, Attrans-Z-(4-methoxycinnamylphthalimide 49.9 ± 2.6 97.0 68.8 ± 6.0 89.1 S122, ethyl trans-Z-(4-methoxycinnamylphthalimide, acid tetra(n-butyl)ammonium salt 52.1 ± 1.0 11.1 72.2 ± 10.6 93.7 S122, trans-Z-(4-hydroxyphenyl)ethenylsulphonate 36.6 ± 1.8 75.1 60.9 ± 0.8 70.0 68.6 ± 6.0 89.1 S122, trans-Z-Methoxycinnamyliotroxamic acid 17.4 ± 0.9* 38.8 25.6 ± 2.0* 10.2 13.2 17.4 13.2 13.4 101.3 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4 15.2 13.4 ± 0.3* 17.4	TS114, diethyl trans-2-(4-hydroxyphenyl)-vinylphosphonate	55.4 ± 1.0	107.8	76.5 ± 5.6	99.2
15116, <i>ItA-couranary</i> 24.3 ± 1.5* 47.2 39.3 ± 3.5* 51.0 15117, <i>Jara-couranary</i> 49.8 ± 1.6 96.9 73.1 ± 2.0 94.9 15118, <i>Jara-s-tuenboxy</i> (nanary/lydhalimide 59.0 ± 0.4 114.7 83.8 ± 1.7 108.8 15119, <i>Jara-s-tuenboxy</i> (nany/lydhalimide 49.9 ± 2.6 97.0 68.6 ± 6.0 89.1 15122, ethyl <i>trans-2-(4-hydroxyphery</i>)(=therylsulphonic acid tetra(<i>n</i> -buty)(Jammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 109.0 79.0 15124, <i>trans-4</i> -(4-hydroxyphery)(letherylsulphonic acid tetra(<i>n</i> -buty)(Jammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 79.0 15124, <i>trans-4</i> -hydroxyphery)(letherylsulphonic acid tetra(<i>n</i> -buty)(Jammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 15124, <i>trans-4</i> -hydroxymphery)(letherylsulphonic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 15125, <i>trans-4</i> -methoxycinanary alk achd 7.8 ± 0.2* 15.2 13.4 ± 0.3* 17.4 15126, <i>trans-4</i> -methoxycinanary alk achd 7.5 ± 0.7* 25.0 10.9 ± 4.4* 14.7 15127, <i>trans-3</i> -dydroxycinnamohydroxamic acid 12.0 ± 0.4* 39.8 20.2 ± 1.3* 27.4	TS115, trans-2-(4-hydroxyphenyl)-vinylphosphonic acid	57.9 ± 1.6	112.7	79.6 ± 3.3	103.2
15117, jara-cournarylamine 49.8 ± 1.6 96.9 73.1 ± 2.0 94.9 15118, J-(4-methoxycinnamylyphthalimide 59.0 ± 0.4 114.7 83.8 ± 1.7 108.8 15119, J-(4-methoxycinnamylyphthalimide 49.9 ± 2.6 97.0 66.6 ± 6.0 85.1 15121, trans-2-(4-methoxycinnamylyphthalimide) 52.1 ± 0.0 111.1 72.2 ± 10.6 93.7 15122, trans-2-(4-hydroxyphenyl)-ethenylsubphonate 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 15124, trans-4-hydroxyntenyl)-ethenylsubphonate 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 15124, trans-4-methoxycinnamylydroxamic acid 17.4 ± 0.9* 33.8 25.6 ± 2.0* 33.2 15125, trans-4-methoxycinnamylydroxamic acid 21.0 ± 3.0* 40.8 35.1 ± 3.4 10.4 15127, trans-4-methoxycinnamylydroxamic acid 21.0 ± 3.0* 40.8 35.1 ± 3.0* 45.6 MM 30.1 ± 6.9 7.4 ± 0.7* 25.0 10.9 ± 4.4* 14.7 15128, trans-4-methoxycinnamylydroxamic acid 21.0 ± 3.0* 40.8 35.1 ± 3.0* 45.6 15127, trans-4-methoxycinnamylydroxamic acid 12.0 ± 0.4 39.8 20.2 ± 1.3* 77.3 <td>TS116, N-(para-coumaryl)phthalimide</td> <td>$24.3 \pm 1.5^*$</td> <td>47.2</td> <td>$39.3 \pm 3.5^*$</td> <td>51.0</td>	TS116, N-(para-coumaryl)phthalimide	$24.3 \pm 1.5^*$	47.2	$39.3 \pm 3.5^*$	51.0
T5118, <i>Hr</i> , 44-methoxycinnamylybrhalimide 59.0 ± 0.4 114.7 83.8 ± 1.7 108.8 T5119, <i>trans</i> -temboxycinnamylybrhalimide 47.8 ± 3.2 93.0 68.2 ± 10.4 88.5 T5120, <i>trans</i> -2-(4-methoxyphenyl)-ethenylsulphoniz edi teta(<i>n</i> -butyl)ammonium salt 57.1 ± 10.0 11.1 72.2 ± 10.6 93.7 T5122, <i>trans</i> -2-(4-hydroxyphenyl)-ethenylsulphoniz edi teta(<i>n</i> -butyl)ammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.3 T5124, <i>trans</i> -2-(4-hydroxyphenyl)-ethenylsulphoniz edi teta(<i>n</i> -butyl)ammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 T5124, <i>trans</i> -4-methoxycinnamylydroxamic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 T5126, <i>trans</i> -4-methoxycinnamylydroxamic acid 7.4 ± 0.9* 33.8 2.5 6 ± 2.0* 33.2 T5126, <i>trans</i> -4-methoxycinnamolydroxamic acid 7.6 ± 0.7* 25.0 10.9 ± 4.4* 14.7 T5129, <i>trans</i> -3-hydroxycinnamolydroxamic acid 12.0 ± 0.4* 39.8 20.2 ± 1.3* 27.3 T5129, <i>trans</i> -3-hydroxycinnamolydroxamic acid 12.0 ± 0.4* 39.8 20.2 ± 1.3* 27.3 T5129, <i>trans</i> -4-divdroxycinnamolydroxamic acid 12.0 ± 0.4* 39.8 20.2 ± 1.3* 27.3 <t< td=""><td>TS117, para-coumarylamine</td><td>49.8 ± 1.6</td><td>96.9</td><td>73.1 ± 2.0</td><td>94.9</td></t<>	TS117, para-coumarylamine	49.8 ± 1.6	96.9	73.1 ± 2.0	94.9
T5119, trans-4-methoxycinnamylamine 47.8 ± 3.2 93.0 68.2 ± 10.4 88.5 T5120, ethyl trans-2-(4-methoxyphenyl)ethenylsulphonic acid tetra(n-butyl)ammonium salt 57.1 ± 10.0 11.1 72.2 ± 10.6 93.7 T5121, trans-2-(4-methoxyphenyl)ethenylsulphonic acid tetra(n-butyl)ammonium salt 57.1 ± 10.0 11.1 72.2 ± 10.6 93.7 T5122, trans-2-(4-hydroxyphenyl)ethenylsulphonic acid tetra(n-butyl)ammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 T5124, trans-2-(4-hydroxyphenyl)ethenylsulphonic acid tetra(n-butyl)ammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 T5125, trans-4-methoxycinnamolydroxamic acid 17.4 ± 0.9* 33.8 25.6 ± 2.0* 33.2 T5127, trans-4-methoxycinnamolydroxamic acid 7.8 ± 0.7* 15.2 13.4 ± 0.3* 17.4 T5128, trans-4-bromocinnamolydroxamic acid 7.5 ± 0.7* 25.0 10.9 ± 4.4* 14.7 T5129, trans-3-hydroxycinnamolydroxamic acid 28.7 ± 2.5 95.6 41.0 ± 1.1* 52.4 T1310, trans-3-hydroxycinnamolydroxamic acid 12.3 ± 0.2* 32.7 ± 2.6 59.9 ± 1.4* 77.7 ± 5.8 T5130, trans-3-hydroxycinnamolydroxamic acid 12.3 ± 0.2* 32.7 ± 1.3* 77.2 ± 6.3	TS118, N-(4-methoxycinnamyl)phthalimide	59.0 ± 0.4	114.7	83.8 ± 1.7	108.8
T1210, trans-2-4-methoxyphenyl-ethenylsulphonate49.9 ± 2.697.068.6 ± 6.068.1T1211, trans-2-4-hydroxyphenyl-ethenylsulphonate38.6 ± 1.875.160.9 ± 0.879.0T122, ethyl trans-2-(4-hydroxyphenyl)-ethenylsulphonate38.6 ± 1.875.160.9 ± 0.879.0T1212, trans-2-(4-hydroxyphenyl)-ethenylsulphonic acid tetra(n-butyl)ammonium salt52.3 ± 2.0101.677.7 ± 6.8100.8T124, trans-4-hydroxymphenyl-ethenylsulphonic acid tetra(n-butyl)ammonium salt52.3 ± 2.0101.677.7 ± 6.8101.3T124, trans-4-methoxycinnamyl alcohol7.8 ± 0.2*15.213.4 ± 0.3*17.417.4T126, trans-4-methoxycinnamyl alcohol7.8 ± 0.2*15.213.4 ± 0.3*17.4T127, trans-3-indoleacrylohydroxamic acid21.0 ± 3.0*40.835.1 ± 3.0*45.6MM30.1 ± 6.974.0 ± 7.979.019.217.4 ± 0.7*25.010.9 ± 4.4*14.7T127, trans-3-hydroxycinnamohydroxamic acid12.0 ± 0.439.820.2 ± 1.3*27.314.1*55.4T1310, trans-3-Hydroxycinnamohydroxamic acid12.3 ± 0.2*32.744.2 ± 2.9*77.7T1312, trans-3-4-hydroxycinnamohydroxamic acid12.3 ± 0.2*32.744.2 ± 2.9*77.7T1312, trans-3-4-hydroxycinnamohydroxamic acid12.3 ± 0.2*32.744.2 ± 2.9*77.7T132, trans-3-4-hydroxycinnamohydroxamic acid12.3 ± 0.2*32.744.2 ± 2.9*77.7T132, trans-3-4-hydroxycinnamohydroxamic acid12.3 ± 0.2*33.353.8 ± 2.9* <td< td=""><td>TS119, trans-4-methoxycinnamylamine</td><td>47.8 ± 3.2</td><td>93.0</td><td>68.2 ± 10.4</td><td>88.5</td></td<>	TS119, trans-4-methoxycinnamylamine	47.8 ± 3.2	93.0	68.2 ± 10.4	88.5
T121, trans-2-(4-methoxypheny)Lethenylsulphonic acid tetra(n-buty)Jammonium salt 57.1 ± 10.0 111.1 72.2 ± 10.6 93.7 T5122, ethyl trans-2-(4-hydroxypheny)Lethenylsulphonic acid tetra(n-buty)Jammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 T5124, trans-2-(4-hydroxypheny)Lethenylsulphonic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 T5124, trans-2-(4-hydroxypheny)Lethenylsulphonic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 T5125, trans-4-methoxycinnamyl-alcohol 7.8 ± 0.2* 15.2 13.4 ± 0.3* 17.4 T5127, trans-4-hydroxymic acid 21.0 ± 3.0* 40.8 35.1 ± 3.0* 45.6 M 30.1 ± 6.9 74.0 ± 7.9 71.1 ± 2.5* 71.4 ± 0.8* 20.2 10.9 ± 4.4* 14.7 T5129, trans-7-hydroxycinnamohydroxamic acid 20.2 ± 0.4* 39.8 20.2 ± 1.3* 27.3 151.0* 151.2 11.1* 55.4 20.2* 21.6 ± 0.6* 22.2 M 151.1* 71.7 ± 2.6 56.9 ± 1.4 17.7 151.3* 151.3* 17.3* 151.3* 17.4 ± 0.6* 22.2 M 151.2* 17.1 ± 2.5* 30.1 150.9* 14.2 ± 0.9* 77.7 <td>TS120, ethyl trans-2-(4-methoxyphenyl)-ethenylsulphonate</td> <td>49.9 ± 2.6</td> <td>97.0</td> <td>68.6 ± 6.0</td> <td>89.1</td>	TS120, ethyl trans-2-(4-methoxyphenyl)-ethenylsulphonate	49.9 ± 2.6	97.0	68.6 ± 6.0	89.1
15122 ethyl trans-2-(4-hydroxyphenyl)ethenylsulphoniz 36.6 ± 1.8 75.1 60.9 ± 0.8 79.0 15123, trans-2-(4-hydroxyphenyl)ethenylsulphoniz acid 52.3 ± 2.0 10.6 77.7 ± 6.8 100.8 15124, trans-4-hydroxymethyl/cinnamic acid $17.4\pm 0.9^*$ 33.8 $25.6\pm 2.0^*$ 33.2 15125, trans-4-methoxycinnamyl alcohol $7.4\pm 0.2^*$ 15.2 $13.4\pm 0.3^*$ 17.4 15126, trans-4-methoxycinnamyl alcohol $7.6\pm 0.2^*$ 15.2 $13.4\pm 0.3^*$ 17.4 15126, trans-4-methoxycinnamyl alcohol $7.5\pm 0.7^*$ 25.0 $10.9\pm 4.4^*$ 14.7 15127, trans-3-hydroxycinnamohydroxamic acid $7.5\pm 0.7^*$ 25.0 $10.9\pm 4.4^*$ 14.7 15129, trans-3-hydroxycinnamohydroxamic acid $7.5\pm 0.7^*$ 25.0 $10.9\pm 4.4^*$ 14.7 15129, trans-3-hydroxycinnamohydroxamic acid $7.5\pm 0.7^*$ 25.0 $10.9\pm 4.4^*$ 14.7 15129, trans-3-hydroxycinnamohydroxamic acid $7.5\pm 0.7^*$ 25.0 $10.9\pm 4.4^*$ 14.7 15120, trans-3-hydroxycinnamohydroxamic acid $12.0\pm 0.4^*$ 32.7 $44.2\pm 2.9^*$ 77.7 15132, trans-3-4-hydroxycinnamohydroxamic acid $12.3\pm 0.2^*$ 32.7 $44.2\pm 2.9^*$ 77.7 15132, trans-3-4-hydroxycinnamohydroxamic acid $12.3\pm 0.2^*$ 32.7 $44.2\pm 2.9^*$ 77.7 15132, trans-3-(4-hydroxyphenyl)erylohydrazide $7.2\pm 0.9^*$ 92.7 $17.1\pm 2.5^*$ 30.1 M 73.7 ± 5.3 $53.3\pm 2.2.9^*$ 58.4 59.3 $53.3\pm 3.2\pm 2.9^*$ 58.4 M	TS121, trans-2-(4-methoxyphenyl)ethenylsulphonic acid tetra(n-butyl)ammonium salt	57.1 ± 10.0	111.1	72.2 ± 10.6	93.7
TS123 trans-2-(4-hydroxypheny)bethenysluphonic acid tetra(n-buty))ammonium salt 52.3 ± 2.0 101.6 77.7 ± 6.8 100.8 TS124, trans-4-hydroxymethylcinnamic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 TS125, trans-4-methoxycinnamohydroxamic acid 7.4 ± 0.9* 33.8 25.6 ± 2.0* 33.2 TS125, trans-4-methoxycinnamohydroxamic acid 7.8 ± 0.2* 15.2 13.4 ± 0.3* 17.4 TS127, trans-4-indoleacrylohydroxamic acid 7.5 ± 0.7* 25.0 10.9 ± 4.4* 14.7 TS128, trans-4-bromocinnamohydroxamic acid 7.5 ± 0.7* 25.0 10.9 ± 4.4* 14.7 TS128, trans-3-hydroxycinnamohydroxamic acid 2.0 ± 0.4 39.8 20.2 ± 1.3* 27.3 TS131, trans-3-hydroxycinnamohydroxamic acid 2.7 42.2 ± 2.9* 77.7 15.1 15.1 77.1 ± 2.6 56.9 ± 1.4 17.1 15.1 15.1 15.1 15.1 15.1 15.1 ± 3.0* 30.1 ± 6.3 92.1 ± 17.1 15.1 15.1 ± 3.0* 30.1 ± 6.3 92.1 ± 17.1 15.1 15.1 ± 3.0* 15.1 ± 3.0* 15.1 ± 3.0* 30.1 ± 6.3 15.1 ± 3.0* 30.1 ± 6.3 15.1 ± 3.0* 15.1 ± 3.0* 30.1 ± 6.3 15.1	TS122, ethyl trans-2-(4-hydroxyphenyl)-ethenylsulphonate	38.6 ± 1.8	75.1	60.9 ± 0.8	79.0
TS124, trans-4-hydroxymethylcinnamic acid 44.9 ± 3.5 87.2 78.1 ± 3.4 101.3 TS125, trans-4-methoxycinnamylakohol 7.8 ± 0.9* 33.8 25.6 ± 2.0* 33.2 TS125, trans-4-methoxycinnamylakohol 7.8 ± 0.2* 15.2 13.4 ± 0.3* 17.4 TS127, trans-3-indoleacrylohydroxamic acid 21.0 ± 3.0* 40.8 35.1 ± 3.0* 45.6 MM 30.1 ± 6.9 74.0 ± 7.9 75.1 ± 7.7* 25.0 10.9 ± 4.4* 14.7 TS128, trans-4-bromocinnamohydroxamic acid 12.0 ± 0.4 39.8 20.2 ± 1.3* 27.3 TS120, trans-3-hydroxycinnamohydroxamic acid 28.7 ± 2.5 55.6 41.0 ± 1.1* 55.4 TS120, trans-3-hydroxycinnamohydroxamic acid 12.3 ± 0.2* 32.7 44.2 ± 2.9* 77.7 TS131, trans-3(-4-hydroxyphenyl)acrylohydrazide 7.2 ± 0.9* 19.2 17.1 ± 2.5* 35.1 MM 7.7 ± 0.6 35.3 53.8 ± 2.9* 58.4 MM 75.9 ± 1.7 TS132, trans-3(-4-hydroxyphenyl)acrylohydrazide 72.1 ± 0.5* 35.3 53.8 ± 2.9* 58.4 MM 57.9 ± 1.7 15.4 ± 4.5 150.3 53.8 ± 2.9* 58.4 MM <td>TS123. <i>trans</i>-2-(4-hydroxyphenyl)ethenylsulphonic acid tetra(<i>n</i>-butyl)ammonium salt</td> <td>52.3 ± 2.0</td> <td>101.6</td> <td>77.7 ± 6.8</td> <td>100.8</td>	TS123. <i>trans</i> -2-(4-hydroxyphenyl)ethenylsulphonic acid tetra(<i>n</i> -butyl)ammonium salt	52.3 ± 2.0	101.6	77.7 ± 6.8	100.8
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS124. <i>trans</i> -4-hydroxymethylcinnamic acid	44.9 ± 3.5	87.2	78.1 + 3.4	101.3
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TS125 <i>trans</i> -4-methoxycinnamohydroxamic acid	$17.4 \pm 0.9^{*}$	33.8	25.6 + 2.0*	33.2
17127, trans-3-indolear/optimum/photoxamic acid10 ± 0.110 ± 0.110 ± 0.111 trans17127, trans-3-indolear/optimum/photoxamic acid21.0 ± 3.0*40.835.1 ± 3.0*45.6MM30.1 ± 6.974.0 ± 7.917128, trans-2-hydroxycinnamohydroxamic acid7.5 ± 0.7*25.010.9 ± 4.4*14.717129, trans-3-hydroxycinnamohydroxamic acid12.0 ± 0.439.820.2 ± 1.3*27.3175130, trans-3-hydroxycinnamohydroxamic acid6.1 ± 0.8*20.216.4 ± 0.6*22.2MM37.7 ± 2.656.9 ± 1.47.7175132, trans-3-(4-hydroxychonydroxamic acid7.2 ± 0.9*19.217.1 ± 2.5*30.1175132, trans-3-(4-hydroxyphenyl)acrylohydrazide7.2 ± 0.9*19.217.1 ± 2.5*30.1175132, cinnamyl alcohol27.8 ± 5.0*35.353.8 ± 2.9*58.4MM7.9 ± 1.7165.4 ± 4.511.3146.8 ± 4.5175032, n/-(4-fluorocinnamyl)phthalimide7.8 ± 0.*35.353.8 ± 2.9*58.4MM5.9 ± 1.7165.4 ± 4.511.3146.8 ± 6.188.715039, N/-(4-dimethylaminocinnamyl)phthalimide47.6 ± 1.4*82.2120.6 ± 4.4*72.915042, N/-(2-methoxycinnamyl)phthalimide47.6 ± 1.4*82.2120.6 ± 4.4*72.915138, N/-(2-methoxycinnamyl)phthalimide64.4 ± 3.7*63.0148.1 ± 10.089.615139, 3-phenyloropionohydroxamic acid50.9 ± 1.8*40.536.2 ± 6.5*24.215044, trans-4-formylcinnamohydroxamic acid50.9 ± 1.8*<	TS126 <i>trans</i> -4-methoxycinnamyl alcohol	$78 \pm 0.2^{*}$	15.2	$13.4 \pm 0.3^{*}$	17.4
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS127 <i>trans</i> -3-indoleactylobydroxamic acid	$210 \pm 30^{*}$	40.8	35 1 + 3 0*	45.6
MiniDist 10.5 140 ± 1.5 TS128, trans-4-bromocinnamohydroxamic acid7.5 \pm 0.7*25.0 $10.9 \pm 4.4^*$ 14.7 TS129, trans-2-hydroxycinnamohydroxamic acid 28.7 ± 2.5 95.6 $41.0 \pm 1.1^*$ 25.3TS131, trans-3-hydroxycinnamohydroxamic acid $6.1 \pm 0.8^*$ 20.2 $16.4 \pm 0.6^*$ 22.2 MM 37.7 ± 2.6 56.9 ± 1.4 5131 , trans-3-4-dhydroxycinnamohydroxamic acid $12.3 \pm 0.2^*$ 32.7 $44.2 \pm 2.9^*$ 77.7 TS132, trans-3-(4-hydroxychenyl)acrylohydrazide $7.2 \pm 0.9^*$ 19.2 $17.1 \pm 2.5^*$ 30.1 MM 78.7 ± 6.3 92.1 ± 17.1 1532 , trans-3-(4-hydroxychenyl)acrylohydrazide $7.2 \pm 0.9^*$ 19.2 $71.1 \pm 2.5^*$ 30.1 MM 78.7 ± 6.3 92.1 ± 17.1 1532 , trans-3-(4-hydroxychenyl)acrylohydrazide $7.8 \pm 5.0^*$ 35.3 $53.8 \pm 2.9^*$ 58.4 MM 77.9 ± 1.7 165.4 ± 4.5 1532 , trans-3-(4-hydroxychenyl)phthalimide $70.8 \pm 2.1^*$ $12.3 \pm 0.2^*$ 32.7 $44.2 \pm 2.9^*$ 78.7 TS032, N/-(4-fluorocinnamyl)phthalimide $70.8 \pm 2.1^*$ $12.3 \pm 0.2^*$ 32.7 $44.2 \pm 2.9^*$ 78.7 TS034, N/-(2-methoxycinnamyl)phthalimide 49.6 ± 3.2 85.7 $136.1 \pm 5.4^*$ 82.3 TS042, N/-2 methoxycinnamyl)phthalimide $44.5 \pm 1.4^*$ 82.2 $120.6 \pm 4.8^*$ 72.9^* TS042, N/-2 -methoxycinnamyl)phthalimide $44.5 \pm 1.4^*$ 82.8 $64.7 \pm 2.1^*$ 39.1 TS042, trans-4-formylcinnamohydroxamic acid $50.0 \pm 2.4^*$	MM	30.1 + 6.9	40.0	710+79	45.0
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	TC128 trans 4 bromosinnamobudrovamis asid	75+07*	25.0	10.0 ± 1.0	147
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS120, trans-4-biomocrimanionydioxamic acid	12.0 ± 0.7	20.0	10.5 ± 4.4 20.2 + 1.3*	27.3
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS129, trans-2-itydroxyclimanonydroxamic acid	12.0 ± 0.4	05.0	20.2 ± 1.5 41.0 ± 1.1*	27.3
15131, trans-3-4-dinydroxychinalitolydroxanic acid0.110.320.210.410.022.2MM37.72.656.91.4TS132, trans-3-(4-hydroxyphenyl)acrylohydrazide12.3 $\pm 0.2^*$ 32.744.2 2.9^* 77.7TS133, trans-3-(4-hydroxyphenyl)acrylohydrazide7.2 $\pm 0.9^*$ 19.217.1 $\pm 2.5^*$ 30.1MM78.7 ± 6.3 92.1 ± 1.7 1513.8 $\pm 2.9^*$ 58.4MM77.9165.44.550.913.3 $\pm 1.3^*$ 78.8TS032, cinnamyl alcohol27.8 5.0^* 35.353.8 $\pm 2.9^*$ 58.4MM70.8 $\pm 2.1^*$ 122.4138.9 $\pm 1.0^*$ 84.0TS033, N/-(4-fluorocinnamyl)phthalimide70.8 $\pm 2.1^*$ 122.4138.9 $\pm 1.0^*$ 84.0TS040, N-(4-dimethylaminocinnamyl)phthalimide70.8 $\pm 1.4^*$ 82.2120.6 $\pm 4.8^*$ 72.9TS042, N-(2-methoxycinnamyl)phthalimide47.6 $\pm 1.4^*$ 82.2120.6 $\pm 4.8^*$ 72.9TS042, N-(2-methoxycinnamyl)phthalimide64.4 $\pm 3.7^*$ 63.0148.1 ± 10.0 89.6TS138, N-(2-hydroxyethyl)-A-hydroxycinnamanide36.4 $\pm 3.7^*$ 63.0148.1 ± 10.0 89.6TS134, trans-4-fluorocinnamylamine43.5 ± 0.9 84.618.3149.222.2TS044, trans-4-fluorocinnamylamine43.5 ± 0.9 84.6118.319.179.3TS044, trans-4-	TSTSU, <i>Udits</i> -S-Hyuruxychinidiionyuruxdiiic dciu TSTS1 trans 2.4 dibudrouwsinnamobudrovamis asid	20.7 ± 2.3 6 1 ± 0.9*	95.0	41.0 ± 1.1 16.4 ± 0.6*	33.4 22.2
MMM 37.7 ± 2.0 30.9 ± 1.4 TS132, trans-cinnamohydroxamic acid $12.3 \pm 0.2^*$ 32.7 $44.2 \pm 2.9^*$ 77.7 TS133, trans-3-(4-hydroxyphenyl)acrylohydrazide $7.2 \pm 0.9^*$ 19.2 $17.1 \pm 2.5^*$ 30.1 MM 78.7 ± 6.3 92.1 ± 17.1 TS032, cinnamyl alcohol $7.8 \pm 5.0^*$ 35.3 $53.8 \pm 2.9^*$ 58.4 MM 79.9 ± 1.7 165.4 ± 4.5 TS037, N-(4-fluorocinnamyl)phthalimide 51.6 ± 3.2 89.1 $130.3 \pm 1.3^*$ 78.8 TS039, N-(4-aiminocinnamyl)phthalimide $70.8 \pm 2.1^*$ 122.4 $138.9 \pm 1.0^*$ 84.0 TS044, N-(2-methoxycinnamyl)phthalimide 49.6 ± 3.2 85.7 $136.1 \pm 5.4^*$ 82.3 TS041, N-(2-methoxycinnamyl)phthalimide $47.6 \pm 1.4^*$ 82.2 $120.6 \pm 4.8^*$ 72.9 TS042, N-(3-methoxycinnamyl)phthalimide 64.4 ± 5.8 111.3 146.8 ± 6.1 88.7 TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide $36.4 \pm 3.7^*$ 63.0 148.1 ± 10.0 89.6 TS139, 3-phenylpropionohydroxamic acid $7.9 \pm 1.3^*$ 82.8 $64.7 \pm 2.1^*$ 39.1 TS146, trans-4-finuocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS137, N-methyl-4-hydroxycinnamamide $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS146, trans-4-fluorocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS147, trans-4-fluorocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS147, trans-4-	ISISI, <i>Udiis</i> -S,4-uiliyuluxyuliidiiluliyuluxdiilic duu	0.1 ± 0.8	20.2	10.4 ± 0.0	22.2
15132, trans-chnamonyoroxamic acid12.3 \pm 0.2"32.744.2 \pm 2.9"77.7TS133, trans-3-(4-hydroxyphenyl)acrylohydrazide7.2 \pm 0.9"19.217.1 \pm 2.5"30.1MM78.7 \pm 6.392.1 \pm 17.115032, cinnamyl alcohol27.8 \pm 5.0"35.353.8 \pm 2.9"58.4MM57.9 \pm 1.7165.4 \pm 4.5130.3 \pm 1.3"78.858.4TS037, N-(4-fluorocinnamyl)phthalimide51.6 \pm 3.289.1130.3 \pm 1.3"78.8TS039, N-(4-aminocinnamyl)phthalimide70.8 \pm 2.1"122.4138.9 \pm 1.0"84.0TS040, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4"82.3TS041, N-(2-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide36.4 \pm 3.7"63.0148.1 \pm 10.089.6TS149, trans-4-formylcinnamohydroxamic acid51.5 \pm 10.9149.2 \pm 22.215044, trans-4-fluorocinnamylamine43.5 \pm 0.984.6118.3 \pm 19.179.3TS046, trans-4-fluorocinnamylamine43.5 \pm 0.984.6118.3 \pm 19.179.3TS044, trans-4-fluorocinnamylamine43.5 \pm 0.984.6118.3 \pm 19.179.3TS045, trans-4-fluorocinnamylamine20.9 \pm 1.8"40.536.2 \pm 6.5"24.2TS137, N-methyl-4-hydroxycinnamamide23.4 \pm 1.045.474.0 \pm 5.6"24.2TS143, 2-phenoxyacetohydroxamic acid23.4 \pm 1.045.474.0 \pm 5.6"24.2 <tr <tr="">TS144, trans-</tr>		57.7 ± 2.0	22.7	50.9 ± 1.4	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	IS IS2, trans-cinnamonydroxamic acid	$12.3 \pm 0.2^{\circ}$	32.7	44.2 ± 2.9"	//./
MM78.7 \pm 6.392.1 \pm 17.1TS032, cinnamyl alcohol27.8 \pm 5.0*35.353.8 \pm 2.9*58.4TS037, N-(4-fluorocinnamyl)phthalimide57.9 \pm 1.7165.4 \pm 4.5TS039, N-(4-aminocinnamyl)phthalimide70.8 \pm 2.1*122.4138.9 \pm 1.0*84.0TS040, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4*82.3TS041, N-(2-methoxycinnamyl)phthalimide47.6 \pm 1.4*82.2120.6 \pm 4.8*72.9TS042, N-(3-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxycthyl)-4-hydroxycinnamamide36.4 \pm 3.7*63.0148.1 ± 10.089.6TS139, 3-phenylpropionohydroxamic acid47.9 \pm 1.3*82.864.7 ± 2.1*39.1TS146, trans-4-formylcinnamohydroxamic acid50.0 ± 2.4*86.493.7 ± 5.7*56.6MM51.5 ± 10.9149.2 ± 22.2140.6 ± 6.994.2TS044, trans-4-fluorocinnamylamine45.9 ± 3.989.3109.6 ± 19.873.4TS047, trans-4-dimethylaminocinnamylamine20.9 ± 1.8*40.536.2 ± 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide47.4 ± 2.592.1140.6 ± 6.994.2TS137, N-methyl-4-hydroxycinnamamide23.4 ± 1.045.474.0 ± 5.6*49.6TS146, trans-4-dimethylaminocinnamylamine23.4 ± 1.045.474.0 ± 5.6*49.6TS147, trans-4-dimethylaminocinnamylamine23.4 ± 1.045.474.0 ± 5.6*49.6TS147, trans-4-dimethylaminocinnamylamine23.4 ± 1.0<	ISI33, trans-3-(4-hydroxyphenyi)acrylonydrazide	7.2 ± 0.9 °	19.2	17.1±2.5"	30.1
15032, cinnamyl alcohol 27.8 ± 5.0* 35.3 53.8 ± 2.9* 58.4 MM 57.9 ± 1.7 165.4 ± 4.5 TS037, N-(4-fluorocinnamyl)phthalimide 51.6 ± 3.2 89.1 130.3 ± 1.3* 78.8 TS039, N-(4-aminocinnamyl)phthalimide 70.8 ± 2.1* 122.4 138.9 ± 1.0* 84.0 TS040, N-(4-dimethylaminocinnamyl)phthalimide 49.6 ± 3.2 85.7 136.1 ± 5.4* 82.3 TS041, N-(2-methoxycinnamyl)phthalimide 47.6 ± 1.4* 82.2 120.6 ± 4.8* 72.9 TS042, N-(3-methoxycinnamyl)phthalimide 64.4 ± 5.8 111.3 146.8 ± 6.1 88.7 TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide 36.4 ± 3.7* 63.0 148.1 ± 10.0 89.6 TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide 50.0 ± 2.4* 86.4 93.7 ± 5.7* 56.6 MM 51.5 ± 10.9 149.2 ± 22.2 120.6 ± 1.8* 79.3 15046, trans-4-fiormylcinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS044, trans-4-filomocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-dimethylaminocinnamylamine 20.9 ± 1.8* 40.5 36.2 ± 6.5* <		/8./±6.3		92.1±17.1	
MM57.9 \pm 1.7165.4 \pm 4.5TSO37, N-(4-fluorocinnamyl)phthalimide51.6 \pm 3.289.1130.3 \pm 1.3*78.8TSO39, N-(4-aminocinnamyl)phthalimide70.8 \pm 2.1*122.4138.9 \pm 1.0*84.0TSO4D, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4*82.3TSO41, N-(2-methoxycinnamyl)phthalimide47.6 \pm 1.4*82.2120.6 \pm 4.8*72.9TSO42, N-(3-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide36.4 \pm 3.7*63.0148.1 \pm 10.089.6TS139, 3-phenylpropionohydroxamic acid47.9 \pm 1.3*82.864.7 \pm 2.1*39.1TS146, <i>trans</i> -4-finurocinnamylamine51.5 \pm 10.9149.2 \pm 22.215044, <i>trans</i> -4-filuorocinnamylamine15.5 \pm 10.9149.2 \pm 22.2TS044, <i>trans</i> -4-filuorocinnamylamine43.5 \pm 0.984.6118.3 \pm 19.179.3TS046, <i>trans</i> -4-aminocinnamylamine20.9 \pm 1.8*40.536.2 \pm 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide23.4 \pm 1.045.4 \pm 74.0 \pm 5.6*49.6TS146, <i>trans</i> -4-dimethylaminocinnamylamine20.9 \pm 1.8*40.536.2 \pm 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide23.4 \pm 1.045.4 \pm 74.0 \pm 5.6*49.6TS164, <i>trans</i> -4-(benzylcarbonyl)phenylcyclopropane-1-carboxylic acid101.9 \pm 7.7*198.1198.9 \pm 1.8*TS165, <i>trans</i> -2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid101.9 \pm 7.7*30.9 </td <td>ISU32, cinnamyl alcohol</td> <td>$27.8 \pm 5.0^{\circ}$</td> <td>35.3</td> <td>53.8 ± 2.9²</td> <td>58.4</td>	ISU32, cinnamyl alcohol	$27.8 \pm 5.0^{\circ}$	35.3	53.8 ± 2.9 ²	58.4
1503, N-(4-fluorocinnamyl)phthalimide51.6 \pm 3.289.1130.3 \pm 1.3*78.8TS039, N-(4-aminocinnamyl)phthalimide70.8 \pm 2.1*122.4138.9 \pm 1.0*84.0TS040, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4*82.3TS041, N-(2-methoxycinnamyl)phthalimide47.6 \pm 1.4*82.2120.6 \pm 4.8*72.9TS042, N-(3-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide36.4 \pm 3.7*63.0148.1 \pm 10.089.6TS139, 3-phenylpropionohydroxamic acid47.9 \pm 1.3*82.864.7 \pm 2.1*39.1TS146, trans-4-formylcinnamohydroxamic acid50.0 \pm 2.4*86.493.7 \pm 5.7*56.6MM51.5 \pm 10.9149.2 \pm 22.215044, trans-4-fluorocinnamylamine45.9 \pm 3.989.3109.6 \pm 19.873.4TS046, trans-4-aminocinnamylamine20.9 \pm 1.8*40.536.2 \pm 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide47.4 \pm 2.592.1140.6 \pm 6.994.2TS143, 2-phenoxyacetohydroxamic acid23.4 \pm 1.045.474.0 \pm 5.6*49.6TS145, trans-4-dimethylaminocinnamylamine23.4 \pm 1.045.474.0 \pm 5.6*49.6TS143, 2-phenoxyacetohydroxamic acid101.9 \pm 7.9*198.1198.9 \pm 1.8133.3TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid101.9 \pm 7.9*30.92.9 \pm 1.8*30.6TS165, trans-2-(4'-benzylcarbonyl)pheny		57.9 ± 1.7		165.4 ± 4.5	
TS039, N-(4-aminocinnamyl)phthalimide70.8 \pm 2.1*122.4138.9 \pm 1.0*84.0TS040, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4*82.3TS041, N-(2-methoxycinnamyl)phthalimide47.6 \pm 1.4*82.2120.6 \pm 4.8*72.9TS042, N-(3-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide36.4 \pm 3.7*63.0148.1 \pm 10.089.6TS139, 3-phenylpropionohydroxamic acid47.9 \pm 1.3*82.864.7 \pm 2.1*39.1TS146, trans-4-formylcinnamohydproxamic acid50.0 \pm 2.4*86.493.7 \pm 5.7*56.6MM51.5 \pm 10.9149.2 \pm 22.2TS044, trans-4-fluorocinnamylamine45.9 \pm 3.989.3109.6 \pm 19.873.4TS047, trans-4-aminocinnamylamine20.9 \pm 1.8*40.536.2 \pm 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide47.4 \pm 2.592.1140.6 \pm 6.994.2TS137, N-methyl-4-hydroxycinnamamide23.4 \pm 1.045.474.0 \pm 5.6*49.6TS164, trans-4-dimethylaminocinnamylamine23.4 \pm 1.045.474.0 \pm 5.6*49.6TS143, 2-phenoxyacetohydroxamic acid101.9 \pm 7.9*198.1198.9 \pm 1.8133.3TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid101.9 \pm 7.9*30.92.9 \pm 1.8*30.6TS164, trans-4-(denzylcarbonyl)phenylcyclopropane-1-carboxylic acid15.9 \pm 1.2*30.92.9 \pm 1.8*15.4	ISO37, N-(4-fluorocinnamyl)phthalimide	51.6 ± 3.2	89.1	$130.3 \pm 1.3*$	/8.8
TS040, N-(4-dimethylaminocinnamyl)phthalimide49.6 \pm 3.285.7136.1 \pm 5.4*82.3TS041, N-(2-methoxycinnamyl)phthalimide47.6 \pm 1.4*82.2120.6 \pm 4.8*72.9TS042, N-(3-methoxycinnamyl)phthalimide64.4 \pm 5.8111.3146.8 \pm 6.188.7TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide36.4 \pm 3.7*63.0148.1 \pm 10.089.6TS139, 3-phenylpropionohydroxamic acid47.9 \pm 1.3*82.864.7 \pm 2.1*39.1TS146, trans-4-formylcinnamohydroxamic acid50.0 \pm 2.4*86.493.7 \pm 5.7*56.6MM51.5 \pm 10.9149.2 \pm 22.215044, trans-4-filorocinnamylamine43.5 \pm 0.984.6118.3 \pm 19.179.3TS046, trans-4-aminocinnamylamine20.9 \pm 1.8*40.536.2 \pm 6.5*24.2TS137, N-methyl-4-hydroxycinnamamide47.4 \pm 2.592.1140.6 \pm 6.994.2TS143, 2-phenoxyacetohydroxamic acid23.4 \pm 1.045.474.0 \pm 5.6*49.6TS145, trans-4-dimethylaminocinnamylamine23.4 \pm 1.045.474.0 \pm 5.6*49.6TS143, 2-phenoxyacetohydroxamic acid101.9 \pm 7.9*198.1198.9 \pm 1.8133.3TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid19.4 \pm 0.2*37.645.6 \pm 1.6*30.6p-Coumaric acid15.9 \pm 1.2*30.92.9 \pm 1.8*15.415.4	IS039, N-(4-aminocinnamyl)phthalimide	$70.8 \pm 2.1*$	122.4	$138.9 \pm 1.0^*$	84.0
TS041, N-(2-methoxycinnamyl)phthalimide $47.6 \pm 1.4^*$ 82.2 $120.6 \pm 4.8^*$ 72.9 TS042, N-(3-methoxycinnamyl)phthalimide 64.4 ± 5.8 111.3 146.8 ± 6.1 88.7 TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide $36.4 \pm 3.7^*$ 63.0 148.1 ± 10.0 89.6 TS139, 3-phenylpropionohydroxamic acid $47.9 \pm 1.3^*$ 82.8 $64.7 \pm 2.1^*$ 39.1 TS146, trans-4-fourocinnamylamine $50.0 \pm 2.4^*$ 86.4 $93.7 \pm 5.7^*$ 56.6 MM 51.5 ± 10.9 149.2 ± 22.2 TS044, trans-4-fluorocinnamylamine 43.5 ± 0.9 84.6 118.3 ± 19.1 79.3 TS046, trans-4-aminocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-dimethylaminocinnamylamine $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS137, N-methyl-4-hydroxycinnamamide 23.4 ± 1.0 45.4 $74.0 \pm 5.6^*$ 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid $101.9 \pm 7.9^*$ 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)chenylcyclopropane-1-carboxylic acid $19.4 \pm 0.2^*$ 37.6 $45.6 \pm 1.6^*$ 30.6	TS040, N-(4-dimethylaminocinnamyl)phthalimide	49.6 ± 3.2	85.7	136.1 ± 5.4*	82.3
TS042, N-(3-methoxycinnamyl)phthalimide 64.4 ± 5.8 111.3 146.8 ± 6.1 88.7 TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide $36.4 \pm 3.7^*$ 63.0 148.1 ± 10.0 89.6 TS139, 3-phenylpropionohydroxamic acid $47.9 \pm 1.3^*$ 82.8 $64.7 \pm 2.1^*$ 39.1 TS146, trans-4-formylcinnamohydroxamic acid $50.0 \pm 2.4^*$ 86.4 $93.7 \pm 5.7^*$ 56.6 MM 51.5 ± 10.9 149.2 ± 22.2 149.2 ± 22.2 TS044, trans-4-fluorocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-aminocinnamylamine $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS137, N-methyl-4-hydroxycinnamamide 27.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 $74.0 \pm 5.6^*$ 49.6 TS164, trans-4-(benzylcarbonyl)phenylcyclopropane-1-carboxylic acid $101.9 \pm 7.9^*$ 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid $15.9 \pm 1.2^*$ 30.9 $22.9 \pm 1.8^*$ 50.4	TS041, N-(2-methoxycinnamyl)phthalimide	$47.6 \pm 1.4^*$	82.2	$120.6 \pm 4.8^*$	72.9
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	TS042, N-(3-methoxycinnamyl)phthalimide	64.4 ± 5.8	111.3	146.8 ± 6.1	88.7
TS139, 3-phenylpropionohydroxamic acid $47.9 \pm 1.3^*$ 82.8 $64.7 \pm 2.1^*$ 39.1 TS146, trans-4-formylcinnamohydroxamic acid $50.0 \pm 2.4^*$ 86.4 $93.7 \pm 5.7^*$ 56.6 MM 51.5 ± 10.9 149.2 ± 22.2 TS044, trans-4-fluorocinnamylamine 43.5 ± 0.9 84.6 118.3 ± 19.1 79.3 TS047, trans-4-aminocinnamylamine $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS137, N-methyl-4-hydroxycinnamamide 27.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 $74.0 \pm 5.6^*$ 49.6 TS165, trans-2-(4'-benzylcarbonyl)chnnamic acid $101.9 \pm 7.9^*$ 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)chnomic acid $15.9 \pm 1.2^*$ 30.9 $22.9 \pm 1.8^*$ 30.6	TS138, N-(2-hydroxyethyl)-4-hydroxycinnamamide	$36.4 \pm 3.7^*$	63.0	148.1 ± 10.0	89.6
$\begin{array}{cccc} {\rm TS146}, {\it trans-4-formylcinnamohydroxamic acid} & 50.0 \pm 2.4^{*} & 86.4 & 93.7 \pm 5.7^{*} & 56.6 \\ {\rm MM} & 51.5 \pm 10.9 & 149.2 \pm 22.2 \\ {\rm TS044}, {\it trans-4-fluorocinnamylamine} & 43.5 \pm 0.9 & 84.6 & 118.3 \pm 19.1 & 79.3 \\ {\rm TS046}, {\it trans-4-aminocinnamylamine} & 45.9 \pm 3.9 & 89.3 & 109.6 \pm 19.8 & 73.4 \\ {\rm TS047}, {\it trans-4-dimethylaminocinnamylamine} & 20.9 \pm 1.8^{*} & 40.5 & 36.2 \pm 6.5^{*} & 24.2 \\ {\rm TS137}, N-methyl-4-hydroxycinnamamide & 47.4 \pm 2.5 & 92.1 & 140.6 \pm 6.9 & 94.2 \\ {\rm TS143}, 2-phenoxyacetohydroxamic acid & 23.4 \pm 1.0 & 45.4 & 74.0 \pm 5.6^{*} & 49.6 \\ {\rm TS164}, {\it trans-4-(benzylcarbonyl)cinnamic acid & 101.9 \pm 7.9^{*} & 198.1 & 198.9 \pm 1.8 & 133.3 \\ {\rm TS165}, {\it trans-2-(4'-benzylcarbonyl)cinnamic acid & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\it trans-2-idi-benzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS164}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\it trans-4-idenzylcarbonyl} & 15.9 \pm 1.2^{*} & 30.9 & 22.9 \pm 1.8^{*} & 15.4 \\ {\rm TS165}, {\tt TS165},$	TS139, 3-phenylpropionohydroxamic acid	$47.9 \pm 1.3^*$	82.8	64.7 ± 2.1*	39.1
MM 51.5 ± 10.9 149.2 ± 22.2 TS044, trans-4-fluorocinnamylamine 43.5 ± 0.9 84.6 118.3 ± 19.1 79.3 TS046, trans-4-aminocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-dimethylaminocinnamylamine $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS137, N-methyl-4-hydroxycinnamamide 47.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 $74.0 \pm 5.6^*$ 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid $101.9 \pm 7.9^*$ 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid $19.4 \pm 0.2^*$ 37.6 $45.6 \pm 1.6^*$ 30.6 p -Coumaric acid $15.9 + 1.2^*$ 30.9 $22.9 + 1.8^*$ 15.4	TS146, trans-4-formylcinnamohydroxamic acid	$50.0 \pm 2.4^*$	86.4	93.7 ± 5.7*	56.6
TS044, trans-4-fluorocinnamylamine 43.5 ± 0.9 84.6 118.3 ± 19.1 79.3 TS046, trans-4-aminocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-dimethylaminocinnamylamine $20.9 \pm 1.8^*$ 40.5 $36.2 \pm 6.5^*$ 24.2 TS137, N-methyl-4-hydroxycinnamamide 47.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 $74.0 \pm 5.6^*$ 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid $101.9 \pm 7.9^*$ 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid $15.9 \pm 1.2^*$ 37.6 $45.6 \pm 1.6^*$ 30.6	MM	51.5 ± 10.9		149.2 ± 22.2	
TS046, trans-4-aminocinnamylamine 45.9 ± 3.9 89.3 109.6 ± 19.8 73.4 TS047, trans-4-dimethylaminocinnamylamine 20.9 ± 1.8* 40.5 36.2 ± 6.5* 24.2 TS137, N-methyl-4-hydroxycinnamamide 47.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 74.0 ± 5.6* 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid 101.9 ± 7.9* 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 ± 0.2* 37.6 45.6 ± 1.6* 30.6 p-Coumaric acid 15.9 + 1.2* 30.9 22.9 ± 1.8* 15.4	TS044, trans-4-fluorocinnamylamine	43.5 ± 0.9	84.6	118.3 ± 19.1	79.3
TS047, trans-4-dimethylaminocinnamylamine 20.9 ± 1.8* 40.5 36.2 ± 6.5* 24.2 TS137, N-methyl-4-hydroxycinnamamide 47.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 74.0 ± 5.6* 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid 101.9 ± 7.9* 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 ± 0.2* 37.6 45.6 ± 1.6* 30.6 p-Coumaric acid 15.9 + 1.2* 30.9 22.9 + 1.8* 15.4	TS046, trans-4-aminocinnamylamine	45.9 ± 3.9	89.3	109.6 ± 19.8	73.4
TS137, N-methyl-4-hydroxycinnamamide 47.4 ± 2.5 92.1 140.6 ± 6.9 94.2 TS137, N-methyl-4-hydroxycinnamamide 23.4 ± 1.0 45.4 74.0 ± 5.6* 49.6 TS164, trans-4-(benzylcarbonyl)cinnamic acid 101.9 ± 7.9* 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 ± 0.2* 37.6 45.6 ± 1.6* 30.6 p-Coumaric acid 15.9 + 1.2* 30.9 22.9 + 1.8* 15.4	TS047. trans-4-dimethylaminocinnamylamine	20.9 ± 1.8*	40.5	$36.2 \pm 6.5^*$	24.2
TS143, 2-phenoxyacetohydroxamic acid 23.4 ± 1.0 45.4 74.0 ± 5.6* 49.6 TS164, <i>trans</i> -4-(benzylcarbonyl)cinamic acid 101.9 ± 7.9* 198.1 198.9 ± 1.8 133.3 TS165, <i>trans</i> -2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 ± 0.2* 37.6 45.6 ± 1.6* 30.6 <i>p</i> -Coumaric acid 15.9 ± 1.2* 30.9 22.9 ± 1.8* 15.4	TS137, N-methyl-4-hydroxycinnamamide	47.4 ± 2.5	92.1	140.6 ± 6.9	94.2
TS164, trans-4-(benzylcarbonyl)cinnamic acid 101.9 ± 7.9* 198.1 198.9 ± 1.8 133.3 TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 ± 0.2* 37.6 45.6 ± 1.6* 30.6 p-Coumaric acid 15.9 + 1.2* 30.9 22.9 + 1.8* 15.4	TS143. 2-phenoxyacetohydroxamic acid	23.4 ± 1.0	45.4	74.0 + 5.6*	49.6
TS165, trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid 19.4 \pm 0.2* 37.6 45.6 \pm 1.6* 30.6 p-Coumaric acid 15.9 \pm 1.2* 30.9 22.9 \pm 1.8* 15.4	TS164 trans-4-(benzylcarbonyl)cinnamic acid	$1019 + 79^*$	198.1	198 9 + 1 8	133.3
P-Countrie add 15.9+1.2* 30.9 22.9+1.8* 154	TS165 trans-2-(4'-benzylcarbonyl)phenylcyclopropane-1-carboxylic acid	19.4 + 0.2*	37.6	456+16*	30.6
	<i>p</i> -Coumaric acid	15.9 ± 1.2*	30.9	22.9 + 1.8*	15.4

*Statistically significant differences in green fluorescent protein (GFP) mean fluorescence intensity (MFI) between bacterial cells grown in MM and MM supplemented with the different compounds (P < 0.01, Student's *t*-test).

 \pm *Dickeya dadantii* 3937 cells carrying the GFP reporter pPhrpA were used in this study. The promoter activities at 12 and 24 h of bacterial growth were determined. GFP MFI was determined for gated populations of bacterial cells by flow cytometry. Values are representative of two independent experiments, and three replicates were used for each experiment. §The relative promoter activity of *hrpA* in *D. dadantii* 3937 cells grown in MM supplemented with 100 μ M of the indicated compounds compared with that in MM (indicated by '%MM') was calculated by the formula: %MM = 100 × MFI(compound)/MFI(MM).

Fig. 3 Effectiveness of TS103 and *p*-coumaric acid (PCA) to inhibit *hrpA* promoter activity. *hrpA* promoter activity of *Dickeya dadantii* was determined in the presence of TS103 or PCA at the respective concentrations. The IC_{50} of these compounds represents the inhibition of 50% of the promoter activity of *hrpA* compared with the dimethylsulphoxide (DMSO) control. The data are representative of two independent experiments. Three replicates were used in each experiment.

Table 3The expression of type III secretionsystem (T3SS) genes hrpA, hrpN, hrpS, hrpL andrpoN of Dickeya dadantii 3937 (3937) inT3SS-inducing medium (MM) and MMsupplemented with TS103 (MM103).



		Average MFI \pm SI	D for growth	in the indicate	d medium†	t			
	12 h			24 h					
Strain	MM	MM103	%MM§	MM	MM103	%MM§			
3937 (pPhrpA) 3937 (pPhrpN) 3937 (pPhrpS) 3937 (pPhrpL) 3937 (pPrpoN) 2037 (pAT)	58.7 ± 6.1 46.8 ± 2.9 73.2 ± 0.6 20.2 ± 1.8 215.3 ± 26.1 4.2 ± 0.5	$8.9 \pm 0.7^{*}$ $5.8 \pm 0.7^{*}$ $27.7 \pm 1.5^{*}$ $7.6 \pm 0.2^{*}$ 175.8 ± 15.5 2.0 ± 0.6	15.2 12.4 37.8 37.6	$66.5 \pm 5.4 \\ 49.9 \pm 2.1 \\ 90.9 \pm 1.2 \\ 21.5 \pm 0.5 \\+ \\ 5.7 \pm 1.8 \\+ \\ \\ \\ \\ \\$	$8.9 \pm 0.2^{*}$ $5.4 \pm 0.3^{*}$ $26.4 \pm 0.6^{*}$ $7.7 \pm 0.2^{*}$ 	13.4 10.8 29.0 35.8			

*Statistically significant differences in green fluorescent protein (GFP) intensity between bacterial cells grown in MM (MM) and MM supplemented with 100 μ M TS103 (MM103) (P < 0.01, Student's t-test).

 $^+$ The promoter activities were compared in MM and MM supplemented with 100 μ M TS103 at 12 and 24 h of bacterial growth. GFP mean fluorescence intensity (MFI) was determined for gated populations of bacterial cells by flow cytometry. Values are representative of two independent experiments, and three replicates were used for each experiment.

‡-, not determined.

§The relative promoter activity of *hrp* genes in *D. dadantii* 3937 cells grown in MM supplemented with 100 μ M TS103 compared with that in MM (indicated by '%MM') was calculated by the formula: %MM = 100 \times MFI(MM103)/MFI(MM).

0.221, P = 0.049) and hrpN (relative expression ratio 0.276, P = 0.049) mRNA levels in the cells grown in MM supplemented with TS103 compared with that in MM (Fig. 4). HrpN protein production was further analysed by Western blot in the presence of TS103. Compared with that in MM, less HrpN was detected in protein extracts from *D. dadantii* 3937 grown in MM supplemented with TS103 (Fig. 5). These results demonstrate that TS103 inhibits *hrpA* and *hrpN* expression and HrpN protein production.

TS103 inhibits *hrpL* transcription through both HrpS and RpoN

In *D. dadantii*, HrpL is a master regulator that controls the expression of genes encoding T3SS -associated filamentous structure and harpin proteins (Chatterjee *et al.*, 2002; Wei *et al.*, 1992; Yang *et al.*, 2010; Yap *et al.*, 2005). We hypothesize that TS103 lowers the level of *hrpL* transcription, which further leads to a decrease in the expression of *hrpA* and *hrpN*. To test this, the promoter activity of *hrpL* was investigated in cells in the presence and absence of TS103. About a three-fold decrease in *hrpL* promoter activity was observed in the cells grown in MM supplemented with TS103 inhib-

its *hrpL* at the transcriptional level. Previous reports have shown that HrpS, a σ^{54} enhancer-binding protein, interacts with the σ^{54} (RpoN)-containing RNA polymerase holoenzyme and initiates the transcription of *hrpL* (Chatterjee *et al.*, 2002; Yap *et al.*, 2005). As TS103 inhibits *hrpL* promoter activity, expression levels of *hrpS* and *rpoN* were examined in cells grown in MM supplemented with TS103 and in MM. Interestingly, a reduction in *hrpS* promoter activity was observed in the cells grown in MM supplemented with TS103 compared with that in MM, whereas *rpoN* transcriptional levels were similar (Table 3). qRT-PCR analysis revealed a significant decrease in *hrpS* (relative expression ratio 0.178, *P* = 0.049) and *rpoN* (relative expression ratio 0.265, *P* = 0.046) mRNA levels in *D. dadantii* 3937 grown in MM amended with TS103 in comparison with that in MM (Fig. 4). These results suggest that TS103 inhibits *hrpL* transcription through both *hrpS* and *rpoN*.

TS103 inhibits *hrpL* at the post-transcriptional level through *rsmB*

In addition to the regulation at the transcriptional level through HrpS and RpoN, *hrpL* is also regulated post-transcriptionally by the RsmA–RsmB pair (Chatterjee *et al.*, 2002; Liu *et al.*, 1998). To



Fig. 4 Relative mRNA levels of *hrpA*, *hrpN*, *hrpS*, *hrpL* and *rpoN* as determined by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Relative mRNA levels of *hrpA*, *hrpN*, *hrpS*, *hrpL* and *rpoN* genes of *Dickeya dadantii* 3937 in type III secretion system-inducing medium (MM) supplemented with 100 μ M TS103 (TS103) compared with that in MM (MM). Asterisks indicate statistically significant differences in mRNA level of cells grown in MM supplemented with 100 μ M TS103 compared with that in MM. *rplU* was used as an endogenous control for data analysis (Pfaffl *et al.*, 2002). The data are representative of two independent experiments. Three replicates were used in each experiment.



Fig. 5 HrpN (A) and OpgG (B) protein expression of *Dickeya dadantii* 3937 in type III secretion system-inducing medium (MM) and MM supplemented with TS103. Lane 1, *D. dadantii* 3937 grown in MM; lane 2, *D. dadantii* 3937 grown in MM supplemented with 100 μM TS103.

determine whether TS103 inhibits the expression of *rsmA* and *rsmB*, a Northern blot was performed to examine the RNA levels of *rsmA* and *rsmB* in *D. dadantii* 3937 grown in MM with and without TS103. Similar levels of *rsmA* mRNA were observed in cells grown in MM with and without TS103 (Fig. 6A). However, significantly lower *rsmB* RNA levels were observed in cells grown in MM supplemented with TS103 in comparison with that in MM (Fig. 6B). These results indicate that TS103 inhibits *hrpL* at the post-transcriptional level through *rsmB*.

Given that *hrpS*, *rpoN* and *rsmB* RNA levels were reduced in cells grown in MM supplemented with TS103, the *hrpL* mRNA level was further examined in cells grown in MM supplemented with TS103. qRT-PCR analysis was performed and our data revealed that a significant reduction in the *hrpL* mRNA level (relative expression ratio 0.254, P < 0.05) was observed in cells grown in MM supplemented with TS103 compared with that in MM (Fig. 4). Together, these results suggest that TS103 inhibits *hrpL* through both the HrpS-RpoN and *rsmB*-RsmA pathways, and consequently lowers the expression of HrpL regulon genes, such as *hrpA* and *hrpN*.

TS103 inhibits *hrpS* transcription through phosphorylation of HrpY

The phosphorylation of HrpY is mandatory for the transcriptional activation of hrpS in D. dadantii and other phytopathogens (Nizan-Koren et al., 2003; Yap et al., 2008). The aspartate residue at position 57 (D57) in HrpY has been proven to be the phosphorylation site needed for its activity in Pantoea stewartii ssp. stewartii and Erwinia herbicola pv. gypsophilae (Merighi et al., 2006; Nizan-Koren et al., 2003). We hypothesize that the inhibition of HrpY phosphorylation by TS103 leads to low levels of *hrpS* transcript of *D. dadantii* 3937. To test this, *\(\Delta hrpYD57A\)* was constructed by site-directed mutagenesis, in which the conserved D57 in HrpY was changed by nonconservative substitution to alanine (D57A), and hrpS promoter activity was assayed in both the wild-type and *△hrpY*D57A strains. A lower level of *hrpS* promoter activity was observed in $\Delta hrpYD57A$ in comparison with that in the wild-type strain (Fig. 7). Moreover, similar levels of hrpS promoter activity were observed in $\Delta hrpYD57A$ and $\Delta hrpY$ (Fig. 7). As HrpX/HrpY is the TCSTS that activates the expression of hrpS (Tang et al., 2006), hrpS promoter activity was also determined in $\Delta hrpX$. As expected, in $\Delta hrpX$, the transcription of hrpSwas reduced in comparison with that in the wild-type strain (Fig. 7). Furthermore, the promoter activity of *hrpS* was restored to the wild-type level when $\Delta hrpY$ D57A, $\Delta hrpY$ and $\Delta hrpX$ were complemented with pCLhrpXY in trans (Fig. 7). These results indicate that D57 of HrpY is the phosphorylation site required for the activity of HrpY in D. dadantii 3937. To further investigate whether TS103 inhibits *hrpS* transcription through its influence on the phosphorylation of HrpY, the promoter activity of hrpS was measured in $\Delta hrpYD57A$ grown in MM and MM supplemented with TS103. Similar levels of hrpS promoter activity were observed in Δ hrpYD57A grown in MM and MM supplemented with 100 μ M TS103 (Table 4). Furthermore, similar levels of hrpS promoter activity were observed among $\Delta hrpYD57A$, $\Delta hrpX$ and the wildtype strain when they were grown in MM supplemented with 100 µM TS103 (Table 4). These results indicate that TS103 inhibits hrpS expression through its influence on the phosphorylation of HrpY.

GacS/GacA is another TCSTS that regulates T3SS through the Rsm system (Tang *et al.*, 2006), but has no regulatory effect on HrpS as no significant difference in *hrpS* promoter activity was observed between $\Delta gacA$ and its parental strain when they were grown in MM (Table 4). To demonstrate that TS103-inhibited *hrpS* expression is HrpY specific, we compared the *hrpS* promoter activities in $\Delta gacA$



Fig. 6 The relative RNA levels of *rsmA* and *rsmB* as determined by Northern blot. Cells were cultured in type III secretion system-inducing medium (MM) or MM supplemented with 100 μ M TS103 for 12 h before RNA isolation. rRNA was used as an internal control. (A) Lane 1, 3937 grown in MM; lane 2, 3937 grown in MM supplemented with TS103. (B) Lane 1, 3937 grown in MM; lane 2, 3937 grown in MM supplemented with TS103. (C) Lane 1, Δpnp grown in MM; lane 2, Δpnp grown in MM supplemented with TS103. (D) Lane 1, $\Delta csrD$ grown in MM; lane 2, $\Delta csrD$ grown in MM supplemented with TS103; lane 3, 3937 grown in MM; lane 2, $\Delta csrD$ grown in MM supplemented with TS103; lane 3, 3937 grown in MM. (E) Lane 1, $\Delta kdgR$ (pMLkdgR) grown in MM; lane 2, 3937 (pML123) grown in MM; lane 3, $\Delta kdgR$ (pML123) grown in MM; lane 4, $\Delta kdgR$ (pML123) grown in MM; lane 4, $\Delta kdgR$ (pML123) grown in MM supplemented with TS103. Numbers below the Northern blots indicate the relative intensity of *rsmA/rsmB* RNA provided by ImaqeJ.

Fig. 7 The *hrpS* promoter activity of *Dickeya dadantii* derivatives in type III secretion system-inducing medium (MM) at 12 h of growth. Strains carrying the green fluorescent protein (GFP) reporter pPhrpS were used in this study. The promoter activities at 12 h of bacterial growth were determined. GFP mean fluorescence intensity (MFI) was determined for gated populations of bacterial cells by flow cytometry. Values are representative of two experiments, and three replicates were used for each experiment. Asterisks indicate statistically significant differences in GFP MFI between the wild-type strain and mutants or complementary strains (P < 0.01, Student's *t*-test).



and the wild-type *D. dadantii* 3937 when they were grown in MM supplemented with TS103. The addition of TS103 led to a similar reduction in *hrpS* promoter activity in the $\Delta gacA$ and wild-type strains (Table 4), suggesting that the inhibition of *hrpS* by TS103 is HrpY specific and is not via GacS/GacA. Together, these results suggest that specific inhibition of HrpY phosphorylation by TS103 leads to low levels of *hrpS* transcript of *D. dadantii* 3937.

TS103 inhibits rsmB through unknown regulators

As a reduced level of *rsmB* RNA was observed when *D. dadantii* 3937 was grown in MM supplemented with TS103 compared with that in MM (Fig. 6B), the regulators of *rsmB* by TS103 were further investigated. The TCSTS GacS/GacA has been reported to be the transcriptional regulator of *rsmB* in several bacteria (Liu *et al.*,

	Average N	IFI \pm SD for grow	th in the indicat	indicated medium†		
	12 h		24 h			
Strain	MM	MM103	MM	MM103		
3937 ΔhrpYD57A ΔhrpX ΔgacA	$\begin{array}{c} 92.0 \pm 6.6 \\ 40.7 \pm 1.1 \\ 33.2 \pm 2.0 \\ 94.2 \pm 2.5 \end{array}$	$37.5 \pm 0.9^{*}$ 35.2 ± 0.7 34.2 ± 0.2 $35.9 \pm 1.6^{*}$	63.2 ± 6.4 32.6 ± 1.8 25.5 ± 0.6 57.7 ± 3.0	$\begin{array}{c} 28.5 \pm 1.1^{*} \\ 26.4 \pm 0.5 \\ 25.4 \pm 0.6 \\ 24.5 \pm 0.4^{*} \end{array}$		

 Table 4
 The *hrpS* promoter activity of *Dickeya dadantii* 3937 (3937) and its derivatives in type III secretion system-inducing medium (MM) and MM supplemented with TS103 (MM103).

*Statistically significant differences in green fluorescent protein (GFP) intensity between bacterial cells grown in MM (MM) and MM supplemented with 100 μ M TS103 (MM103) (P < 0.01, Student's *t*-test).

⁺The promoter activities were compared in MM and MM supplemented with 100 μ M TS103 at 12 and 24 h of bacterial growth. GFP mean fluorescence intensity (MFI) was determined for gated populations of bacterial cells by flow cytometry. Values are representative of two independent experiments, and three replicates were used for each experiment.

1999; Mukherjee et al., 2000; Tang et al., 2006). To confirm that rsmB is a GacA regulon gene in D. dadantii 3937, the promoter activity of *rsmB* in $\triangle qacA$ was examined. A dramatic reduction in *rsmB* promoter activity was observed in $\triangle qacA$ compared with the wild-type strain (Table 5). Complementation of $\triangle gacA$ with a gacA gene coupled with its native promoter into the chromosome of the mutant strain at an intergenic region ($\Delta gacA::gacA$) restored the transcription of *rsmB* to near wild-type levels (Table 5). These results demonstrate that GacA is a transcriptional regulator of rsmB in D. dadantii 3937. To investigate whether TS103 inhibits the activity of GacS/GacA, and leads to a lower level of rsmB RNA, the promoter activity of *rsmB* was examined in the wild-type and $\Delta gacA$ strains grown in MM and MM supplemented with TS103. Similar levels of *rsmB* promoter activity were observed in the cells grown in MM and MM supplemented with TS103 (Table 5). These results suggest that GacS/GacA positively regulates rsmB transcription in *D. dadantii* 3937 and the inhibition of TS103 on rsmB does not occur through the transcriptional regulator GacS/GacA.

PNPase plays an important role in reducing *rpoN* mRNA stability and *rsmB* RNA turnover, which, in turn, down-regulates *hrpL* and HrpL regulon genes, such as *hrpA* and *hrpN* in *D. dadantii* 3937 (Zeng *et al.*, 2010). As a significant reduction in *rpoN* mRNA and *rsmB* RNA levels was observed in cells grown in MM supplemented with TS103 compared with that in MM (Figs 4 and 6B), we speculate that TS103 may inhibit T3SS through PNPase. If this is the case, a similar *rsmB* RNA level should be observed in the *pnp* mutant (Δpnp) grown in MM and MM supplemented with TS103. To test this, Northern blot analysis was performed to compare the *rsmB* RNA level in Δpnp grown in MM with and without TS103. Unexpectedly, significantly smaller amounts of *rsmB* RNA were observed in the Δpnp cells grown in TS103 compared with that in MM (Fig. 6C), suggesting that the inhibition of TS103 on *rsmB* is not through PNPase.

CsrD, a regulator of RNA turnover, was found to be essential for the decay of the small RNAs CsrB (homologue of RsmB) and CsrC in *Escherichia coli* (Suzuki *et al.*, 2006). Inactivation of *csrD* resulted in an increase in the *csrB* RNA level (Suzuki *et al.*, 2006). In *D. dadantii*, an increased *rsmB* RNA level was also observed in $\Delta csrD$ compared with the wild-type strain (Fig. 6D), suggesting that CsrD also negatively regulates the *rsmB* RNA level in *D. dadantii*. To determine whether TS103 inhibits *rsmB* RNA through CsrD, Northern blot analysis was performed to compare the *rsmB* RNA levels in $\Delta csrD$ grown in MM with and without TS103. Smaller amounts of *rsmB* RNA were observed in the $\Delta csrD$ cells grown in MM supplemented with TS103 compared with that in MM (Fig. 6D). These results suggest that *csrD* negatively regulates *rsmB* RNA in *D. dadantii* 3937 and the inhibition of TS103 on *rsmB* is not through CsrD.

Our recent work has demonstrated that OpgG, a component of Osmo-regulated periplasmic glucans, positively regulates *rsmB* at the post-transcriptional level in *D. dadantii* (X. Wu *et al.*, in press). To test whether the inhibition of TS103 on *rsmB* is through OpgG, the original promoter and the whole open reading frame (ORF) of *opgG* were fused in frame with the His \times 6 tag, and the OpgG protein level of the wild-type cells grown in MM and MM supplemented with TS103 was examined by Western blot. Similar levels of the OpgG protein were observed in the cells grown in MM and MM supplemented with TS103 (Fig. 5B), suggesting that the inhibition of TS103 on *rsmB* is not through OpgG.

The IcIR-like regulator KdgR has been reported to be a regulator of *rsmB* in *Pectobacterium* (Liu *et al.*, 1999). To study whether KdgR is a regulator of *rsmB* in *D. dadantii* 3937, and whether TS103 inhibits *rsmB* through KdgR, the promoter activity and RNA level of *rsmB* in $\Delta kdgR$ and the wild-type strains were examined. Similar levels of *rsmB* promoter and RNA were observed in $\Delta kdgR$ compared with that in the wild-type strain grown in MM (Table 5 and Fig. 6E). Furthermore, significantly smaller amounts of *rsmB* RNA were observed in $\Delta kdgR$ cells grown in MM supplemented with TS103 compared with that in MM (Fig. 6E). These results suggest that KdgR is not a regulator of *rsmB* in *D. dadantii* 3937 and the inhibition of TS103 on *rsmB* is not through KdgR.

DISCUSSION

The T3SS is an essential virulence factor of many Gram-negative bacterial pathogens. This secretion system has emerged as an attractive target for small-molecule anti-virulence therapeutics (Cegelski *et al.*, 2008; Duncan *et al.*, 2012; Escaich, 2008). Recently, a number of T3SS inhibitors have been identified in multiple bacterial species, including *Yersinia* spp., *Chlamydia* spp., *Salmonella* spp., *Pseudomonas aeruginosa, Erwinia amylovora*

Table 5The *rsmB* promoter activity of *Dickeyadadantii* 3937 (3937) and its derivatives in typeIII secretion system-inducing medium (MM) andMM supplemented with 100 μ M TS103(MM103).

	Avera	ge MFI \pm SD for grow	th in the indicated me	I medium*			
	6 h		12 h				
Strain	MM	MM103	MM	MM103			
3937	1525.3 ± 20.2	1603.4 ± 28.0	2531.4 ± 150.9	2628.6 ± 86.9			
$\Delta qacA$	74.6 ± 2.0	53.5 ± 1.4	86.0 ± 6.7	63.1 ± 4.0			
$\Delta gacA::gacA$	1956.2 ± 140.8	2052.3 ± 60.8	2779.6 ± 48.1	2905.1 ± 104.4			
3937 (pML123)	<u>_</u> †	_	1724.8 ± 9.1	_			
$\Delta k dg R$ (pML123)	_	_	1700.4 ± 12.0	_			
$\Delta k dg R$ (pMLkdgR)	_	—	1582.2 ± 42.0	_			

*The promoter activities were compared in MM and MM supplemented with 100 μ M TS103 at 12 and 24 h of bacterial growth. Green fluorescent protein (GFP) mean fluorescence intensity (MFI) was determined for gated populations of bacterial cells by flow cytometry. Values are representative of two independent experiments, and three replicates were used for each experiment.

†---, not determined.

and D. dadantii, using screening-based approaches under interdisciplinary efforts between chemists and microbiologists (Hudson et al., 2007; Khokhani et al., 2013; Li et al., 2009; Muschiol et al., 2006; Pan et al., 2007; Yamazaki et al., 2012). The T3SS regulatory pathways and regulatory components of D. dadantii are well understood (Lebeau et al., 2008; Li et al., 2010; Yang et al., 2008b, 2010; Yi et al., 2010; Zeng et al., 2010). In this study, D. dadantii 3937 was used to screen high-potency T3SS inhibitors and to identify inhibitor targets in the T3SS pathways. The compound TS103 was found to be a highly potent inhibitor of the T3SS master regulator HrpL via HrpX-HrpY and the rsmB-RsmA regulatory pathway. Although no growth inhibition was observed in TS103 at low concentrations (1 or 10μ M), a further study showed that a slight promotion of bacterial growth was observed in TS103 at higher concentrations (100 µM) (Figs S2 and S3). This indicates that D. dadantii 3937 may possibly use TS103 as a carbon or energy source for growth. Nevertheless, TS103 dramatically inhibits the T3SS at all three concentrations used in this study. It is worth mentioning that TS103 also plays a role in inhibiting the T3SS of other hrp Group I phytobacteria, such as E. amylovora (Khokhani et al., 2013). However, the effect of TS103 on the T3SS of *hrp* Group II phytobacteria remains to be determined.

Bacteria use a wide variety of mechanisms to sense and respond to environmental changes, with TCSTSs being the dominant methods (Calva and Oropeza, 2006). The signal transduction lies in the recognition and interpretation of environmental signals that are related to host infection, and conversion of these signals into specific protein—protein interactions and transcriptional activation (Calva and Oropeza, 2006; Hoch, 2000). HrpX/Y is a TCSTS encoded within the *hrp* gene cluster of *D. dadantii*. HrpX, a transmembrane sensor histidine kinase, senses environmental stimuli and activates its cognate response regulator HrpY by phosphorylation. The phosphorylated HrpY then binds the *hrpS* promoter and promotes the transcription of *hrpS* (Yap *et al.*, 2008). In *P. stewartii* ssp. *stewartii* and *E. herbicola* pv. *gypsophilae*, the aspartate residue at position 57 has been proven

to be the phosphorylation site of HrpY (Merighi et al., 2006; Nizan-Koren et al., 2003). Although there is no direct evidence on the phosphorylation site of HrpY in *D. dadantii*, the HrpY protein without acetyl phosphate treatment was unable to bind the hrpS promoter, suggesting that in vitro phosphorylation is required for HrpY activity in D. dadantii (Yap et al., 2008). In this study, conservative and structurally neutral amino acid substitutions of aspartate to alanine at position 57 reduced the expression of *hrpS* (Table 4 and Fig. 7). In agreement with the observations in P. stewartii ssp. stewartii and E. herbicola pv. gypsophilae, our data suggest that D57 is needed for the activity of HrpY in D. dadantii 3937 and that D57 is the phosphorylation site of HrpY. Moreover, a similar level of hrpS promoter activity was observed in $\Delta hrpYD57A$ grown in MM and MM supplemented with 100 μ M TS103 (Table 4), indicating that TS103 inhibits hrpS transcription through the phosphorylation of HrpY. This is the first report of a phenolic compound targeting the specific phosphorylated response regulator HrpY to inhibit the T3SS.

Rsm, also known as Csr in E. coli, is one of the most studied post-transcriptional regulators in bacteria (Romeo et al., 2012; Timmermans and Van Melderen, 2010). The Rsm/Csr system is present in many plant- and animal-associated pathogenic bacteria (Babitzke and Romeo, 2007; Bejerano-Sagie and Xavier, 2007; Liu et al., 1998; Suzuki et al., 2002; Toledo-Arana et al., 2007). It is composed of two regulatory components: the RNA-binding protein (RsmA in soft rot phytopathogens, RsmA and RsmE in Pseudomonas, CsrA in E. coli) and non-coding regulatory small RNAs (RsmB in soft rot phytopathogens, RsmY and RsmZ in Pseudomonas, CsrB in E. coli) (Gudapaty et al., 2001; Romeo, 1998). The central component of the Rsm/Csr systems is a homodimeric RNA-binding protein (CsrA or RsmA), which either represses or activates the expression of target mRNAs posttranscriptionally (Babitzke and Romeo, 2007; Mercante et al., 2009). A common feature of Rsm/Csr systems is that a TCSTS is responsible for the activation of the transcription of each small RNA in response to an unknown signal(s) (Babitzke and Romeo, 2007). In D. dadantii, the conserved TCSTS GacA/GacS regulates the small RNA RsmB at the transcriptional level (Table 5). In this TCS, GacS, a tripartite sensor histidine kinase, senses environmental stimuli and activates its cognate response regulator, GacA, by phosphorylation, which, in turn, induces the expression of the regulatory small RNA RsmB (Blumer et al., 1999; Cui et al., 2001; Heeb and Haas, 2001). rsmB transcripts then bind to and sequester RsmA, which eventually affects the expression of downstream genes (Chatterjee et al., 2002; Liu et al., 1998). In P. aeruginosa, the authors deduced that TS103 affects the transcripts of the small RNAs rsmY and rsmZ via the activation of GacA through GacS and/or other two-component sensor proteins that cross-talk to GacS/GacA (Yamazaki et al., 2012). Although we speculate that the strong negative effect of TS103 on *rsmB* of *D. dadantii* might involve the interference of GacS/GacA, our observations do not support such a hypothesis, because TS103 has no inhibitory effect on *rsmB* promoter activity in the wild-type strain, whereas *rsmB* promoter activity was dramatically reduced in $\Delta qacA$ compared with that in the wild-type strain (Table 5).

RNA turnover is an important process in the regulation of gene expression and is tightly regulated (Mata et al., 2005). In E. coli, RNA decay is often initiated by an endoribonuclease, RNase E, which preferentially binds to the 5' monophosphorylated terminus of transcripts, with cleavage occurring in A/U-rich regions adjacent to stem-loop structures. The resulting cleavage products are then rapidly degraded by the processive 3' to 5' exoribonucleases PNPase and RNase II (Carpousis, 2007; Romeo et al., 2012). Recently, the turnover of the small RNAs CsrB and CsrC in E. coli was reported to require a novel regulator, CsrD, in addition to RNase E and PNPase (Romeo et al., 2012; Suzuki et al., 2006). In D. dadantii, PNPase also plays an important role in rsmB RNA turnover (Zeng et al., 2010). Consistent with our previous work (X. Wu et al., in press), an increased rsmB RNA level was observed in $\Delta csrD$ compared with that in the wild-type strain (Fig. 6E), suggesting that CsrD negatively regulates the rsmB RNA level in D. dadantii. However, smaller amounts of rsmB RNA were observed in both Δpnp and $\Delta csrD$ cells grown in MM supplemented with TS103 compared with that in MM (Fig. 6C,D), suggesting that the inhibition of TS103 on rsmB RNA is not through CsrD and PNPase. In addition, our recent work found that CsrD regulates the rsmB RNA level through OpgG in D. dadantii (X. Wu et al., in press). In this study, similar levels of OpgG protein were observed in the cells grown in MM and MM supplemented with TS103 (Fig. 5B), suggesting that the inhibition of TS103 on rsmB is not through CsrD. Overall, the knowledge of the posttranscriptional regulators of the small RNA RsmB is limited. Moreover, the regulation of RsmB by TS103 remains to be determined.

In summary, this study screened a series of derivatives of plant phenolic compounds and identified that TS103 has the highest inhibitory potency on T3SS of *D. dadantii*. The effect of TS103 on the regulatory components of the T3SS was further elucidated and

revealed that the inhibition goes through both the HrpX/Y-HrpS-HrpL and *rsmB*-RsmA-HrpL regulatory pathways. To our knowledge, this is the first inhibitor which affects the T3SS through both transcriptional and post-transcriptional pathways in the soft-rot pathogen *D. dadantii* 3937.

EXPERIMENTAL PROCEDURES

Bacterial strains, plasmids, primers and growth conditions

The bacterial strains and plasmids used in this study are listed in Table 1. *Escherichia coli* and *D. dadantii* were grown in Luria–Bertani (LB), MM or mannitol–glutamic acid (MG) medium at 37 °C and 28 °C, respectively (Yang *et al.*, 2007, 2008b; Zeng *et al.*, 2010; Zou *et al.*, 2012). Medium was supplemented with chloramphenicol (20 µg/mL), ampicillin (100 µg/mL), kanamycin (50 µg/mL), spectinomycin (50 µg/mL) and gentamicin (15 µg/mL) when required. The primers used for PCR in this work are listed in Table S1 (see Supporting Information).

Sources of the screened compounds

Compounds TS32 and TS108–TS113 were purchased from commercial sources (Sigma-Aldrich, Louis, MO, USA; Alfa Aesar, Ward Hill, MA, USA or TCI, Cambridge, MA, USA). TS37, TS39–TS42, TS44, TS46 and TS47 were synthesized by the methods described in Methods S1. The remaining compounds were synthesized via the routes described in our recent publications (Khokhani *et al.*, 2013; Yamazaki *et al.*, 2012). DMSO stock solutions were prepared and stored at –20 °C. The compounds were added at a final concentration of 100 μ M, except when indicated otherwise. DMSO was used as a control (indicated by 'MM').

Flow cytometry analysis

Promoter activities of *hrpA*, *hrpN*, *hrpS*, *hrpL*, *rsmB* and *rpoN* were measured by flow cytometry as described previously (Peng *et al.*, 2006). Briefly, the bacterial cells carrying the promoter–GFP transcriptional fusion plasmid were cultured in LB broth at 28 °C overnight and subcultured 1:100 in MM and MM supplemented with compounds in 20-mL glass culture tubes. Samples were diluted to the appropriate concentration with 1 × phosphate-buffered saline (PBS) at 12 and 24 h after inoculation. The promoter activities were analysed by measuring the GFP intensity using flow cytometry (BD Biosciences, San Jose, CA, USA). Meanwhile, the optical density of the samples was also measured at 600 nm (OD₆₀₀) when required.

Construction of plasmids and mutants

The $\Delta gacA$, $\Delta hrpY$ and $\Delta kdgR$ deletion mutants were constructed by marker exchange mutagenesis (Yang *et al.*, 2002). Briefly, two fragments flanking each target gene were obtained. A kanamycin cassette, amplified from pKD4 (Table 1), was ligated with these two fragments and cloned into the *Bam*HI and *Xho*I sites in pWM91. This construct was transferred

Δ*hrp*YD57A, in which the conserved aspartate residue at position 57 in HrpY was changed by nonconservative substitution to alanine, was constructed in a similar manner as above using plasmid phrpYD57A as the PCR template to obtain the flanking fragments, and a kanamycin cassette was placed at the 3' end of the *hrpY* ORF for selection. The plasmid phrpYD57A was constructed as follows. A 1830-bp fragment containing the *hrpY* ORF and its flanking region was amplified using primers hrpYH1 and hrpYH2 and 3937 genome DNA as the template. The PCR fragment was ligated into pGEM-T Easy vector to generate plasmid phrpY. phrpYD57A, bearing a D57A change in *hrpY* primary amino acid sequence, was generated by a QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, La Jolla, CA, USA) according to the manual, using the primers hrpYD57A-Frd and hrpYD57A-RC and phrpY as the template.

To construct plasmids for complementation, the ORF and promoter region of target genes were amplified and cloned into low-copy-number plasmids pML123 or pCL1920 (Table 1). *gacA* was inserted into the chromosome using allelic exchange mutagenesis for complementation. To construct plasmids to complement the *gacA* mutation, the promoter and coding regions of *gacA* were PCR amplified and cloned into the chromosomal integration vector pTCLSCm (Jahn *et al.*, 2008; Yap *et al.*, 2008). The resulting plasmid was electrotransformed into $\Delta gacA$ and allelic exchange was used to insert *gacA* into the chromosome to generate the complementation strain $\Delta gacA$::*gacA* (Jahn *et al.*, 2008). All of the constructs and mutants described above were verified by PCR and DNA sequencing.

Northern blot analysis

About 10 µg of RNA of *D. dadantii* in MM and MM supplemented with TS103 were determined using Northern blot as described previously (Li *et al.*, 2009). In brief, *D. dadantii* was grown in MM and MM supplemented with TS103 for 12 h, total RNA was isolated using TRI reagent and residual DNA was removed with the TURBO DNA-free kit (Ambion, Austin, TX, USA). RNA samples were analysed using biotin-labelled probe and a biotin detection system (BrightStar Psoralen–Biotin and Bright Star BioDetect, Ambion). rRNA was used as an internal control.

qRT-PCR analysis

The mRNA levels were measured by qRT-PCR. *Dickeya dadantii* 3937 was cultured in MM or MM supplemented with 100 μ M TS103 for 12 h. Cells were harvested and total RNA was isolated as described previously (Li *et al.*, 2009; Yang *et al.*, 2008a). The cDNA level of target genes in different samples was quantified by real-time PCR using a Real Master Mix (Eppendorf, Westbury, NY, USA), as described previously (Peng *et al.*, 2006). Data were analysed using a Relative Expression Software Tool (Pfaffl *et al.*, 2002). The expression level of *rplU* was used as an endogenous control for data analysis (Mah *et al.*, 2003).

Western blot analysis

Proteins were separated by 12.5% sodium dodecylsulphatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to an Immobilion poly(vinylidene difluoride) (PVDF) transfer membrane (Millipore, Bedford, MA, USA) using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, Hercules, CA, USA). The blot (immunoblot) was then probed with an anti-HrpN peptide antibody (1:5000) or anti-His polyclonal antibody (1:2000; Southern Biotech, Birmingham, AL, USA). The blot was incubated for 2 h with the primary antibody and then washed in PBS containing 0.1% Tween 20. Antigen—antibody complexes were visualized by incubation of the blots in a 1:5000 dilution of horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibody (Abcam, Cambridge, MA, USA) using an ECL detection system (GE Healthcare UK Ltd, England, UK).

ACKNOWLEDGEMENTS

This work is dedicated to Noel T. Keen. This project was supported by grants from the National Science Foundation (award no. EF-0332163), the Research Growth Initiative of the University of Wisconsin-Milwaukee, the Catalyst Grant in advanced Automation of UWM Research Foundation for Ching-Hong Yang, the National Science Foundation of China (grant No. 21272029) for Xin Chen, the 948 Project of the Ministry of Agriculture, China (grant No. 2011-S8) for Yan Li, and the 111 project B13006, China.

REFERENCES

- Alfano, J.R. and Collmer, A. (1997) The type III (Hrp) secretion pathway of plant pathogenic bacteria: trafficking harpins, Avr proteins, and death. J. Bacteriol. 179, 5655–5662.
- Babitzke, P. and Romeo, T. (2007) CsrB sRNA family: sequestration of RNA-binding regulatory proteins. *Curr. Opin. Microbiol.* **10**, 156–163.
- Bauer, D.W., Bogdanove, A.J., Beer, S.V. and Collmer, A. (1994) Erwinia chrysanthemi hrp genes and their involvement in soft rot pathogenesis and elicitation of the hypersensitive response. *Mol. Plant–Microbe Interact.* 7, 573– 581.
- Bejerano-Sagie, M. and Xavier, K.B. (2007) The role of small RNAs in quorum sensing. *Curr. Opin. Microbiol.* 10, 189–198.
- Blumer, C., Heeb, S., Pessi, G. and Haas, D. (1999) Global GacA-steered control of cyanide and exoprotease production in *Pseudomonas fluorescens* involves specific ribosome binding sites. *Proc. Natl. Acad. Sci. USA*, 96, 14 073–14 078.
- Calva, E. and Oropeza, R. (2006) Two-component signal transduction systems, environmental signals, and virulence. *Microb. Ecol.* 51, 166–176.
- Carpousis, A.J. (2007) The RNA degradosome of *Escherichia coli*: an mRNA-degrading machine assembled on RNase E. *Annu. Rev. Microbiol.* 61, 71–87.
- Cegelski, L., Marshall, G.R., Eldridge, G.R. and Hultgren, S.J. (2008) The biology and future prospects of antivirulence therapies. *Nat. Rev. Microbiol.* 6, 17–27.
- Chatterjee, A., Cui, Y. and Chatterjee, A.K. (2002) Regulation of *Erwinia carotovora* hrpL_{Ecc} (sigma-L_{Ecc}), which encodes an extracytoplasmic function subfamily of sigma factor required for expression of the HRP regulon. *Mol. Plant–Microbe Interact.* 15, 971–980.
- Cornelis, G.R. (2006) The type III secretion injectisome. Nat. Rev. Microbiol. 4, 811– 825.
- Cui, Y., Chatterjee, A., Liu, Y., Dumenyo, C.K. and Chatterjee, A.K. (1995) Identification of a global repressor gene, *rsmA*, of *Erwinia carotovora* subsp. *carotovora* that controls extracellular enzymes, N-(3-oxohexanoyl)-L-homoserine lactone, and pathogenicity in soft-rotting *Erwinia* spp. *J. Bacteriol.* **177**, 5108–5115.
- Cui, Y., Chatterjee, A. and Chatterjee, A.K. (2001) Effects of the two-component system comprising GacA and GacS of *Erwinia carotovora* subsp. *carotovora* on the production of global regulatory *rsmB* RNA, extracellular enzymes, and harpin_{Ecc}. *Mol. Plant–Microbe Interact.* 14, 516–526.

- Datsenko, K.A. and Wanner, B.L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA*, 97, 6640–6645.
- Dixon, R.A. and Paiva, N.L. (1995) Stress-induced phenylpropanoid metabolism. *Plant Cell*, **7**, 1085–1097.
- Duncan, M.C., Linington, R.G. and Auerbuch, V. (2012) Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. *Antimicrob. Agents Chemother.* 56, 5433–5441.
- Escaich, S. (2008) Antivirulence as a new antibacterial approach for chemotherapy. *Curr. Opin. Chem. Biol.* 12, 400–408.
- Feys, B.J. and Parker, J.E. (2000) Interplay of signaling pathways in plant disease resistance. *Trends Genet.* 16, 449–455.
- Galán, J.E. and Collmer, A. (1999) Type III secretion machines: bacterial devices for protein delivery into host cells. *Science*, 284, 1322–1328.
- Ghosh, P. (2004) Process of protein transport by the type III secretion system. *Microbiol. Mol. Biol. Rev.* 68, 771–795.
- Grant, S.R., Fisher, E.J., Chang, J.H., Mole, B.M. and Dangl, J.L. (2006) Subterfuge and manipulation: type III effector proteins of phytopathogenic bacteria. *Annu. Rev. Microbiol.* 60, 425–449.
- Gudapaty, S., Suzuki, K., Wang, X., Babitzke, P. and Romeo, T. (2001) Regulatory interactions of Csr components: the RNA binding protein CsrA activates csrB transcription in Escherichia coli. J. Bacteriol. 183, 6017–6027.
- Hahlbrock, K. and Scheel, D. (1989) Physiology and molecular biology of phenylpropanoid metabolism. Annu. Rev. Plant Biol. 40, 347–369.
- Heeb, S. and Haas, D. (2001) Regulatory roles of the GacS/GacA two-component system in plant-associated and other gram-negative bacteria. *Mol. Plant–Microbe Interact.* 14, 1351–1363.
- Hoch, J.A. (2000) Two-component and phosphorelay signal transduction. Curr. Opin. Microbiol. 3, 165–170.
- Hudson, D.L., Layton, A.N., Field, T.R., Bowen, A.J., Wolf-Watz, H., Elofsson, M., Stevens, M.P. and Galyov, E.E. (2007) Inhibition of type III secretion in *Salmonella enterica* serovar Typhimurium by small-molecule inhibitors. *Antimicrob. Agents Chemother.* 51, 2631–2635.
- Hueck, C.J. (1998) Type III protein secretion systems in bacterial pathogens of animals and plants. *Microbiol. Mol. Biol. Rev.* 62, 379–433.
- Jahn, C.E., Willis, D.K. and Charkowski, A.O. (2008) The flagellar sigma factor fliA is required for Dickeya dadantii virulence. Mol. Plant–Microbe Interact. 21, 1431–1442.
- Khokhani, D., Zhang, C., Li, Y., Wang, Q., Zeng, Q., Yamazaki, A., Hutchins, W., Zhou, S.-S., Chen, X. and Yang, C.-H. (2013) Discovery of plant phenolic compounds that act as type three secretion system inhibitors or inducers of fire blight pathogen *Erwinia amylovora*. Appl. Environ. Microbiol. **79**, 5424–5436.
- Labes, M., Pühler, A. and Simon, R. (1990) A new family of RSF1010-derived expression and *lac*-fusion broad-host-range vectors for Gram-negative bacteria. *Gene*, 89, 37–46.
- Lebeau, A., Reverchon, S., Gaubert, S., Kraepiel, Y., Simond-Cote, E., Nasser, W. and Gijsegem, F.V. (2008) The GacA global regulator is required for the appropriate expression of *Erwinia chrysanthemi* 3937 pathogenicity genes during plant infection. *Environ. Microbiol.* 10, 545–559.
- Lerner, C.G. and Inouye, M. (1990) Low copy number plasmids for regulated low-level expression of cloned genes in *Escherichia coli* with blue/white insert screening capability. *Nucleic Acids Res.* 18, 4631.
- Li, Y., Peng, Q., Selimi, D., Wang, Q., Charkowski, A.O., Chen, X. and Yang, C.-H. (2009) The plant phenolic compound *p*-coumaric acid represses gene expression in the *Dickeya dadantii* type III secretion system. *Appl. Environ. Microbiol.* **75**, 1223– 1228.
- Li, Y., Yamazaki, A., Zou, L., Biddle, E., Zeng, Q., Wang, Y., Lin, H., Wang, Q. and Yang, C.-H. (2010) ClpXP protease regulates the type III secretion system of *Dickeya dadantii* 3937 and is essential for the bacterial virulence. *Mol. Plant–Microbe Interact.* 23, 871–878.
- Liu, Y., Cui, Y.Y., Mukherjee, A. and Chatterjee, A.K. (1998) Characterization of a novel RNA regulator of *Erwinia carotovora* ssp. *carotovora* that controls production of extracellular enzymes and secondary metabolites. *Mol. Microbiol.* 29, 219–234.
- Liu, Y., Jiang, G., Cui, Y., Mukherjee, A., Ma, W.L. and Chatterjee, A.K. (1999) *kdgR_{ecc}* negatively regulates genes for pectinases, cellulase, protease, Harpin_{Ecc}, and a global RNA regulator in *Erwinia carotovora* subsp. *carotovora*. *J. Bacteriol.* **181**, 2411–2421.
- Mah, T.F., Pitts, B., Pellock, B., Walker, G.C., Stewart, P.S. and O'Toole, G.A. (2003) A genetic basis for *Pseudomonas aeruginosa* biofilm antibiotic resistance. *Nature*, 426, 306–310.

- Mata, J., Marguerat, S. and Bähler, J. (2005) Post-transcriptional control of gene expression: a genome-wide perspective. *Trends Biochem. Sci.* 30, 506–514.
- Mercante, J., Edwards, A.N., Dubey, A.K., Babitzke, P. and Romeo, T. (2009) Molecular geometry of CsrA (RsmA) binding to RNA and its implications for regulated expression. J. Mol. Biol. 392, 511–528.
- Merighi, M., Majerczak, D.R., Zianni, M., Tessanne, K. and Coplin, D.L. (2006) Molecular characterization of *Pantoea stewartii* subsp. *stewartii* HrpY, a conserved response regulator of the Hrp type III secretion system, and its interaction with the *hrpS* promoter. J. Bacteriol. 188, 5089–5100.
- Metcalf, W.W., Jiang, W., Daniels, L.L., Kim, S.K., Haldimann, A. and Wanner, B.L. (1996) Conditionally replicative and conjugative plasmids carrying *lacZα* for cloning, mutagenesis, and allele replacement in bacteria. *Plasmid*, **35**, 1–13.
- Miller, W.G., Leveau, J.H. and Lindow, S.E. (2000) Improved gfp and inaZ broadhost-range promoter-probe vectors. Mol. Plant–Microbe Interact. 13, 1243–1250.
- Montesano, M., Brader, G., Ponce, D.E. and Palva, E.T. (2005) Multiple defence signals induced by *Erwinia carotovora* ssp. *carotovora* elicitors in potato. *Mol. Plant Pathol.* 6, 541–549.
- Mukherjee, A., Cui, Y., Ma, W., Liu, Y. and Chatterjee, A.K. (2000) hexA of Erwinia carotovora ssp. carotovora strain Ecc71 negatively regulates production of RpoS and rsmB RNA, a global regulator of extracellular proteins, plant virulence and the quorum-sensing signal, N-(3-oxohexanoyl)-L-homoserine lactone. Environ. Microbiol. 2, 203–215.
- Muschiol, S., Bailey, L., Gylfe, Å., Sundin, C., Hultenby, K., Bergström, S., Elofsson, M., Wolf-Watz, H., Normark, S. and Henriques-Normark, B. (2006) A smallmolecule inhibitor of type III secretion inhibits different stages of the infectious cycle of *Chlamydia trachomatis*. *Proc. Natl. Acad. Sci. USA*, **103**, 14 566–14 571.
- Nasser, W., Reverchon, S., Vedel, R. and Boccara, M. (2005) PecS and PecT coregulate the synthesis of HrpN and pectate lyases, two virulence determinants in *Erwinia chrysanthemi* 3937. *Mol. Plant–Microbe Interact.* 18, 1205–1214.
- Nizan-Koren, R., Manulis, S., Mor, H., Iraki, N. and Barash, I. (2003) The regulatory cascade that activates the Hrp regulon in *Erwinia herbicola* pv. gypsophilae. Mol. *Plant–Microbe Interact.* 16, 249–260.
- Pan, N., Goguen, J. and Lee, C. (2007) High throughput screening for small-molecule inhibitors of type III secretion in *Yersinia pestis*. In: *The Genus Yersinia* (Perry, R.D. and Fetherston, J.D., eds.), pp. 367–375. Berlin: Springer.
- Peng, Q., Yang, S., Charkowski, A.O., Yap, M.N., Steeber, D.A., Keen, N.T. and Yang, C.-H. (2006) Population behavior analysis of *dspE* and *pelD* regulation in *Erwinia chrysanthemi* 3937. *Mol. Plant–Microbe Interact.* **19**, 451–457.
- Pfaffl, M.W., Horgan, G.W. and Dempfle, L. (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. *Nucleic Acids Res.* 30, e36.
- Rasko, D.A. and Sperandio, V. (2010) Anti-virulence strategies to combat bacteriamediated disease. *Nat. Rev. Drug Discov.* 9, 117–128.
- Romeo, T. (1998) Global regulation by the small RNA-binding protein CsrA and the non-coding RNA molecule CsrB. *Mol. Microbiol.* 29, 1321–1330.
- Romeo, T., Vakulskas, C.A. and Babitzke, P. (2012) Post-transcriptional regulation on a global scale: form and function of Csr/Rsm systems. *Environ. Microbiol.* 15, 313–324.
- Sanchez-Romero, J.M., Diaz-Orejas, R. and De Lorenzo, V. (1998) Resistance to tellurite as a selection marker for genetic manipulations of *Pseudomonas* strains. *Appl. Environ. Microbiol.* **64**, 4040–4046.
- Suzuki, K., Wang, X., Weilbacher, T., Pernestig, A.K., Melefors, O., Georgellis, D., Babitzke, P. and Romeo, T. (2002) Regulatory circuitry of the CsrA/CsrB and BarA/UvrY systems of *Escherichia coli*. J. Bacteriol. 184, 5130–5140.
- Suzuki, K., Babitzke, P., Kushner, S.R. and Romeo, T. (2006) Identification of a novel regulatory protein (CsrD) that targets the global regulatory RNAs CsrB and CsrC for degradation by RNase E. *Genes Dev.* 20, 2605–2617.
- Tang, X.Y., Xiao, Y.M. and Zhou, J.M. (2006) Regulation of the type III secretion system in phytopathogenic bacteria. *Mol. Plant–Microbe Interact.* 19, 1159–1166.
- Timmermans, J. and Van Melderen, L. (2010) Post-transcriptional global regulation by CsrA in bacteria. *Cell. Mol. Life Sci.* 67, 2897–2908.
- Toledo-Arana, A., Repoila, F. and Cossart, P. (2007) Small noncoding RNAs controlling pathogenesis. *Curr. Opin. Microbiol.* 10, 182–188.
- Van Loon, L. (2000) Systemic induced resistance. In: Mechanisms of Resistance to Plant Diseases (Slusarenko, A.J. and Fraser, R.S.S., eds.), pp. 521–574. Berlin: Springer.
- Waterman, S.R. and Holden, D.W. (2003) Functions and effectors of the Salmonella pathogenicity island 2 type III secretion system. Cell. Microbiol. 5, 501–511.
- Wei, Z.M., Laby, R.J., Zumoff, C.H., Bauer, D.W., He, S.Y., Collmer, A. and Beer, S.V. (1992) Harpin, elicitor of the hypersensitive response produced by the plant pathogen *Erwinia amylovora. Science*, 257, 85–88.

- Yamazaki, A., Li, J., Zeng, Q., Khokhani, D., Hutchins, W.C., Yost, A.C., Biddle, E., Toone, E.J., Chen, X. and Yang, C.-H. (2012) Derivatives of plant phenolic compound affect the type III secretion system of *Pseudomonas aeruginosa* via a GacS– GacA two-component signal transduction system. *Antimicrob. Agents Chemother*. 56, 36–43.
- Yang, B., Sugio, A. and White, F.F. (2005) Avoidance of host recognition by alterations in the repetitive and C-terminal regions of AvrXa7, a type III effector of *Xanthomonas* oryzae pv. oryzae. Mol. Plant–Microbe Interact. 18, 142–149.
- Yang, C.H., Gavilanes-Ruiz, M., Okinaka, Y., Vedel, R., Berthuy, I., Boccara, M., Chen, J.W.-T., Perna, N.T. and Keen, N.T. (2002) *hrp* genes of *Erwinia chrysanthemi* 3937 are important virulence factors. *Mol. Plant–Microbe Interact.* 15, 472–480.
- Yang, S., Zhang, Q., Guo, J., Charkowski, A.O., Glick, B.R., Ibekwe, A.M., Cooksey, D.A. and Yang, C.-H. (2007) Global effect of indole-3-acetic acid biosynthesis on multiple virulence factors of *Erwinia chrysanthemi* 3937. *Appl. Environ. Microbiol.* 73, 1079–1088.
- Yang, S., Peng, Q., San Francisco, M., Wang, Y., Zeng, Q. and Yang, C.H. (2008a) Type III secretion system genes of *Dickeya dadantii* 3937 are induced by plant phenolic acids. *PLoS ONE*, 3, e2973.
- Yang, S., Peng, Q., Zhang, Q., Yi, X., Choi, C.J., Reedy, R.M., Charkowski, A.O. and Yang, C.-H. (2008b) Dynamic regulation of GacA in type III secretion, pectinase gene expression, pellicle formation, and pathogenicity of *Dickeya dadantii* (*Erwinia chrysanthemi* 3937). *Mol. Plant–Microbe Interact.* 21, 133–142.
- Yang, S., Peng, Q., Zhang, Q., Zou, L., Li, Y., Robert, C., Pritchard, L., Liu, H., Hovey, R., Wang, Q., Birch, P., Toth, I.K. and Yang, C.-H. (2010) Genome-wide identification of HrpL-regulated genes in the necrotrophic phytopathogen *Dickeya dadantii* 3937. *PLoS ONE*, 5, e13472.
- Yap, M.N., Yang, C.H., Barak, J.D., Jahn, C.E. and Charkowski, A.O. (2005) The Erwinia chrysanthemi type III secretion system is required for multicellular behavior. J. Bacteriol. 187, 639–648.
- Yap, M.N., Yang, C.H. and Charkowski, A.O. (2008) The response regulator HrpY of Dickeya dadantii 3937 regulates virulence genes not linked to the hrp cluster. Mol. Plant–Microbe Interact. 21, 304–314.
- Yi, X., Yamazaki, A., Biddle, E., Zeng, Q. and Yang, C.H. (2010) Genetic analysis of two phosphodiesterases reveals cyclic diguanylate regulation of virulence factors in *Dickeya dadantii*. Mol. Microbiol. **77**, 787–800.
- Zeng, Q., Ibekwe, A.M., Biddle, E. and Yang, C.-H. (2010) Regulatory mechanisms of exoribonuclease PNPase and regulatory small RNA on T3SS of *Dickeya dadantii*. *Mol. Plant–Microbe Interact.* 23, 1345–1355.
- Zou, L., Zeng, Q., Lin, H., Gyaneshwar, P., Chen, G. and Yang, C.-H. (2012) SlyA regulates type III secretion system (T3SS) genes in parallel with the T3SS master regulator HrpL in *Dickeya dadantii* 3937. *Appl. Environ. Microbiol.* 78, 2888–2895.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Fig. S1 The relative promoter activity of *hrpA* in *Dickeya dadantii* 3937 cells grown in type III secretion system-inducing medium (MM) supplemented with 10 μ M of the indicated compounds compared with that in MM (indicated by '%MM'). Green fluorescent protein (GFP) mean fluorescence intensity (MFI) was determined for gated populations of bacterial cells by flow cytometry. %MM was calculated by the formula: %MM = 100 × MFI(compound)/ MFI(MM). Asterisks indicate statistically significant difference in *hrpA* promoter activity of *D. dadantii* 3937 cells grown in MM supplemented with 10 μ M of the indicated compounds compared with that in MM. Two independent experiments were performed and three replicates were used for each experiment.

Fig. S2 The growth of Dickeya dadantii 3937 in type III secretion system-inducing medium (MM) and MM supplemented with TS103 at different concentrations at 12 and 24 h. To study the effect of TS103 on bacterial growth, 50 µL of bacterial suspension [optical density at 600 nm $(OD_{600}) = 1.0$] was used as the initial inoculum and added to 5 mL of MM and MM supplemented with TS103. The growth of D. dadantii 3937 was recorded. Results from one representative experiment are shown. Three replicates were used in this experiment, and the experiment was repeated twice. Fig. S3 The growth curve of Dickeya dadantii 3937 in type III secretion system-inducing medium (MM) supplemented with TS103 at different concentrations. To detect the growth curve of D. dadantii 3937 in MM supplemented with TS103 at concentrations of 0, 1, 10 and 100 μ M, overnight cultured bacteria were added to MM and MM supplemented with TS103 [initial inoculum optical density at 600 nm (OD_{600}) = 0.01]. The OD_{600} of *D. dadantii* 3937 was recorded at 2-h intervals. Results from one representative experiment are shown. Three replicates were used in this experiment, and the experiment was repeated twice.

Table S1 Primers used in this study.

Methods S1 General procedure for the preparation of cinnamyl amine derivatives TS37, TS39–TS42, TS44, TS46 and TS47.